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Abstract
The objectives of this thesis were to characterize the biochemical origins of malodour in the
female bladder, elucidate how vaginal Lactobacillus species interact with malodorous
compounds and assess the potential to deliver probiotic strains topically.
Metabolomic tools were used to explore differences between the urine of healthy women and
those positive for Escherichia coli urinary tract infection (UTI). Positive samples had increased
concentrations of the fishy-smelling biogenic amine (BA) trimethylamine (TMA). The BAs
cadaverine, putrescine, and tyramine, causatives of malodour in bacterial vaginosis (BV) were
also quantified. Putrescine was elevated in BV samples. In vitro, the capacity of five
uropathogenic E. coli strains to produce the four BAs of interest was tested. When grown in
human urine, E. coli was shown to produce putrescine and TMA, and also biosynthesize
cadaverine which, might be produced under specific conditions in some patients. This confirmed
that there is an overlap in the malodorous compounds present in the urogenital tract of women
with BV and UTI, two highly prevalent conditions driven by dysbiosis.
The same metabolomic approaches were used to characterize clinical strains of Lactobacillus
crispatus, an abundant species in the healthy vagina. There were no differences in terms of BA
profiles between those isolated from Lactobacillus dominated microbiotas and those from a
dysbiotic vagina. The latter had higher inhibitory activity towards common uropathogens,
potentially due to metabolic adaptation.
The amine-degradation capacity of L. crispatus was further characterized and previous exposure
to BAs led to higher tolerance. Tests with cell-free extracts revealed that bacterial metabolites
alone can reduce the amount BAs. Some strains were able to degrade BAs, while others were
found produce them.
In order to assess the feasibility that malodour-reducing lactobacilli could be placed in a topical
preparation for delivery to the perineal and vulval skin, four different oils were assessed.
Coconut oil and petroleum jelly emerged as the best candidates for retention of viability.
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It is our hope that these findings will help to develop probiotic-based products that not only
restore homeostasis, but also treat the malodour that impairs a woman’s quality of life.

Keywords
Probiotics, Lactobacillus, metabolomics, dysbiosis, urinary tract infections, bacterial vaginosis,
putrescine, cadaverine, tyramine, trimethylamine, biogenic amines.
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Summary for Lay Audience
Yearly, millions of women seek medical advice due to vaginal and urinary foul-smell. The most
common causes are bacterial vaginosis (BV) and urinary tract infection (UTI). Antibiotics are
prescribed but can take several days to provide relief from the odour. This is a major burden for
patients and takes a toll on their life-quality.
A healthy vagina has its own collection of microbes with the most abundant being lactobacilli.
They use the nutrients within the vagina and, in exchange, provide protection to the host
primarily by not allowing the establishment of harmful microbes. When lactobacilli reserves are
reduced there are increased chances of infection.
Some probiotics (‘live bacteria that, when taken in adequate amounts, confer a health benefit on
the host’), such as Lacticaseibacillus rhamnosus GR-1 and Limosilactobacillus reuteri RC-14,
are used to help maintain equilibrium within the vagina, thus, preventing recurrence of infection.
We propose that certain probiotics could be used, alone or in combination with antibiotics, to
target malodour, thereby providing relief sooner. However, not all probiotics are the same and
thorough screening must be carried out to select ones with specific malodour reducing
characteristics.
Here, we investigated compounds known as biogenic amines, which are the culprits of fishy
vaginal and urinary smell. We found that patients with UTI have large quantities of these
chemicals in their urine. We also identified that certain lactobacilli that are common in the
vagina can degrade these compounds.
We suggest the direct application of probiotics through a cream or ointment, such as petroleum
jelly or coconut oil, could allow women to self-manage malodour.
Overall, the findings compiled in this thesis provide a basis for the probiotic industry to develop
products that can combat a major reason for women to seek medical care.
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Chapter 1

1

The focus of the thesis

The female urogenital environment of healthy women is populated mostly by bacteria
from the Lactobacillus genus. These organisms play a key role in maintaining
homeostasis. When equilibrium is disrupted a state of dysbiosis arises, in which
pathogens dominate and infection can occur. The most common conditions resulting from
this disruption in the urogenital microbiome are bacterial vaginosis (BV) and urinary tract
infection (UTI). Each has its own etiology and symptomatic presentation, but both are
accompanied by malodour and both adversely affect quality of life.
Since the early 1980s, administration of lactobacilli has been proposed to help restore and
maintain urogenital health. This is now referred to as a probiotic application. Much is
now known about how lactobacilli can reduce the incidence of BV and UTI but to date
this has not considered effects against malodour (Puebla-Barragan & Reid, 2019).
In this thesis, the relationship between lactobacilli and the compounds that cause
malodour is investigated. In addition, this characteristic of strains was examined with a
view of selecting candidate probiotics. The long-term hope is that lactobacilli can be
applied to rapidly eliminated malodour, even before antibiotics have eradicated the
causative organisms. This would provide a holistic approach for women to manage their
urogenital health.

1.1

The urogenital anatomy and microbiome of women

The female urogenital tract comprises the vulvar region, vagina, cervix, fallopian tubes,
uterus, urethra, bladder, ureters and kidneys (Figure 1.1B). The vulva entails the
structures of the female external genitalia (i.e. mons pubis, labia majora, labia minora,
clitoris, vestibule, Bartholin’s glands, and Skene’s glands) (Figure 1.1A) (Lau et al.,
2021; Nguyen & Duong, 2020; Weinstock, 2012), while the lower urinary tract is formed
by the bladder and the urethra (Mangera et al., 2013). We are studying these areas as a
whole due to their interconnection and anatomic proximity.
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Figure 1.1 The anatomy of the female urogenital tract
The human body is colonized by communities of microorganisms, which are specific to
each anatomical environment. This collection of organisms is known as the human
microbiota (Weinstock, 2012); while the microbiome term takes into account biotic and
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abiotic factors, including microorganism genomes (Cho & Blaser, 2012). An association
has been identified between an increasing number of disease conditions and the human
microbiome (Lau et al., 2021; Weinstock, 2012).
The urogenital tract in women is composed of diverse bacterial communities which live
in a mutualistic relationship where the host provides nutrients to support bacterial growth
and replenishment, and bacteria play key roles in maintaining homeostasis within the
environment. For instance, urine provides a constant influx of nutrients that support its
microbiota, as it is rich in electrolytes, amino acids, and carbohydrates (Bouatra et al.,
2013; Neugent et al., 2020; Parsons et al., 1990). Similarly, the vaginal epithelium and
the cervico-vaginal are rich in mucins, glycogen, and glycoproteins, which provide
nutrients to the vaginal microbiota (Fuochi et al., 2017; Godha et al., 2017; Mirmonsef et
al., 2014). Meanwhile, indigenous Lactobacillus spp. have a protective function by
inhibiting potentially pathogenic organisms from inducing infection (Ma et al., 2012).
Although the vaginal microbiota consists of a range of aerobic and anaerobic
microorganisms, lactobacilli are the most common and numerous (Borges et al., 2014).
The disruption of the vaginal microbiota is known as ‘dysbiosis’, and it is often
associated with clinical conditions such as BV, UTI, infection by human
immunodeficiency virus (HIV), desquamative inflammatory vaginitis, atrophic vaginitis,
vulvovaginal candidiasis (VVC), and trichomoniasis. Vaginal dysbiosis has also been
correlated with adverse pregnancy outcomes such as preterm birth and maternal and
neonatal infections (Van de Wijgert & Jespers, 2017). Urinary tract infection and BV are
the most common reasons for women to visit the doctor. Antibiotics are often prescribed
for these conditions and it is not surprising that the indigenous microbiota are
significantly impacted by these therapies. While prescribed antibiotics are necessary to
treat symptomatic infection, their use as prophylactic agents makes less sense given the
side effects and the fact that no agent is specific for the causative pathogen or primary
symptoms – pain and frequency for UTI, itch for VVC and malodour for BV.
Given the correlation between lactobacilli dominance and health, it makes sense to
consider applying these organisms to the urogenital region as a means to maintain and
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restore well-being. These could be effective as prophylactic measures or as adjunct to
antimicrobial therapy.

1.2

Role of lactobacilli in the urogenital environment

This section contains segments adapted and reproduced with permission (Appendix A)
from: Puebla-Barragan, S., & Reid, G. (2019). Forty-five-year evolution of probiotic
therapy. Microbial cell, 6, 184–196. Supplemental material available for download at:
http://microbialcell.com/researcharticles/2019a-puebla-barragan-microbial-cell/
Efforts to characterize the vaginal microbiota using 16S rRNA gene sequencing, led to
the proposal of five different community types. They were based on Lactobacillus
crispatus, L. iners, L. gasseri, or L. jensenii dominance, plus a group representing a
dysbiotic state (Ravel et al., 2011). However, this approach is problematic for many
reasons. It uses statistical associations to categorize different microbiota profiles, without
considering the health implications of each. It was based on North American subjects,
whereas those from other regions can have different dominant Lactobacillus species. It
also does not aid in identifying which patients require therapeutic intervention (Reid,
2019). Instead, a focus on the function of specific bacterial species and the presence of
specific metabolites such as gamma-hydroxybutyrate or biogenic amines would be more
appropriate (Ma et al., 2012; McMillan et al., 2015; Reid, 2018, 2019).
The long-held belief that beyond the distal urinary tract used was sterile, was proven
incorrect when sequencing techniques identified a urinary microbiota. Similar to the
vagina, the bladder is dominated by Lactobacillus species, along with Gardnerella,
Streptococcus, Corynebacteria, Escherichia, Aerococcus and Staphylococcus, which are
less frequent and normally present in lower abundance (Brubaker & Wolfe, 2016, 2015;
Pearce et al., 2014).
Lactobacillus species are not simply bystanders but play an active role in maintaining the
health of the urogenital environment. They physically compete with pathogens for sites
of adhesion to the urothelium, while also producing antimicrobial compounds such as
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bacteriocins, surfactants, and lactic acid (D’Alessandro et al., 2021; G et al., 2011;
Karaoğlu et al., 2003; Tachedjian et al., 2017)
Lactic acid is the main organic acid produced by lactobacilli. It helps maintain an acid pH
in the vagina which is ideal for lactobacilli maintenance while inhibiting the growth of
pathogens. It is also hypothesized to elicit immunomodulatory effects by increasing antiinflammatory cytokines in cervicovaginal cells and inhibiting pro-inflammatory
mediators associated with HIV (Hearps et al., 2017; Tachedjian et al., 2017).

1.2.1

Bacterial vaginosis

Bacterial vaginosis is one of the most common conditions associated with vaginal
dysbiosis. Its prevalence ranges from 23% to 29% in women across world regions, and
the global economic burden of treating it is estimated to be around US $4.8 billion
(Peebles et al., 2019). It occurs when the abundance of Lactobacillus spp. is diminished,
thereby reducing the concentration of lactic acid and other metabolites, resulting in an
increase in pH and overgrowth of anaerobic pathogenic bacteria. The condition increases
the risk for miscarriage, preterm birth, as well as for acquiring and transmitting HIV
(Eastment & McClelland, 2018; Gustin et al., 2021). It is polymicrobial by nature with
the most common genera being Gardnerella, Prevotella, Atopobium, Megasphera,
Sneathia, and Dialister (McMillan et al., 2015; Ravel et al., 2011).
The Amsel criteria has long been used to diagnose BV using at the presence of at least
three of four criteria: vaginal pH higher than 4.5; presence of epithelial cells covered in
bacteria (clue cells); a positive amine or ‘whiff’ test (fishy odour in vaginal discharge,
before or after 10% KOH is added); and white discharge adherent to the vaginal walls
(Amsel et al., 1983; Spiegel et al., 1983). A second diagnostic method is often used,
albeit this was never its intention. Termed the Nugent test after its author, it consists of a
scoring system based on Gram-stained vaginal smears (Figure 1.2). Depending on the
proportion of Gram positive rods presumed to be lactobacilli versus dense biofilms of
Gram negative rods and Gram positive cocci and smaller rods like Atopobium sp., a score
is designated from 1-10 (Nugent et al., 1991; Spiegel et al., 1983). However, this
approach requires observer training and objectivity (Redelinghuys et al., 2020) and its
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usefulness is being questioned. Since cases of BV can be asymptomatic, the finding of a
Nugent score of 10 does not necessarily mean that antibiotics will be prescribed; the
clinical signs and symptoms must be present. This in itself is a dilemma for physicians as
it is not clear why symptoms would not occur when the microbial milieu is so pathogenic
in abundance. On the other hand, since the antibiotics for BV, namely metronidazole and
clindamycin, are not effective at penetrating the biofilms typically present (on clue cells),
it makes sense not to prescribe drug treatment when the patient has no presenting signs or
symptoms. Furthermore, no effective treatment for malodour exists per se.
Recurrence of BV (and UTI) is common (Foxman, 2014; Ma et al., 2012), debilitating
and with a significant baring on quality of life. One line of investigation that began in
2003 was to administer a L. crispatus strain (CTV-05) to the vagina in the hope that it
would colonize and prevent BV and UTI recurrences (Antonio & Hillier, 2003; Cohen et
al., 2020; Hemmerling et al., 2009, 2010). In clinical studies, this showed promise for
preventing UTI but not sufficiently effective against BV(Czaja et al., 2007). This is
particularly interesting as the hypothesis was that using a species commonly found in the
vagina would be preferable. Notably, Reid and Bruce took a different approach, believing
that the inhibitory capabilities of the lactobacilli were more important than the species,
especially since probiotic organisms do not colonize (Bruce & Reid, 1988; Hill et al.,
2014).
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Figure 1.2 Gram-stained smear of secretions in normal vaginal fluid (top) vs bacterial
vaginosis (bottom) (Beards, 2021)
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1.2.2

Urinary tract infections

The perineum acts as an anatomical barrier between the anus and the urethra. But this is
only approximately 4cm and therefore uropathogens can cross from the anus to the
urethra, bladder and vagina (Stapleton, 2016). This makes it all the more important for
the indigenous strains to be able to out-compete the pathogens as they arrive. Indeed, the
perineum and urethra contain microorganisms which help prevent the ascension of
pathogens into the urinary tract (Bruce et al. 1973; Dong et al., 2011). The majority of
uncomplicated UTIs (80-90%) are caused by Escherichia coli, originating from the
gastrointestinal tract (Salvatore et al., 2011) via the faecal-vaginal-periurethral route
(Moreno et al., 2008). Infections of the lower urinary tract in patients with no
predispositions (structural, metabolic or immunological) are considered uncomplicated
UTIs (Chiu, 2013).
Before a UTI is diagnosed, significant bacteriuria (≥ 105 CFUs/mL of bacteria in a fresh
urine specimen (Chiu, 2013)), as well as symptoms and signs must be present. These
signs and symptoms may vary, but the more common are: dysuria, urgency, increased
frequency of urination, abdominal pain, and malodour (Chiu, 2013; Sj et al., 2004). It has
been estimated that UTI occurs in over a third of the female population during their
lifetime (Salvatore et al., 2011). Moreover, due to anatomical differences and easier
access of pathogens from the anus, UTIs are more common in females than in males due
to anatomical differences (i.e. the urethra is much shorter in females) (Chiu, 2013).
The urethra and the bladder form the lower urinary tract in women (Mangera et al.,
2013), while the upper tract is composed of the kidneys and ureters which drain to the
bladder (Saint-Elie et al., 2010). The anatomical location of infection as well as its
severity are the basis of the classification of UTIs (Chiu, 2013). Lower UTIs include
cystitis and acute urethral syndrome typically treated with oral antibiotics (Salvatore et
al., 2011).
Upper UTI (also known as pyelonephritis) occurs due to an invasive infection of the renal
parenchyma. It is characterized by fever, renal angle tenderness, nausea, and vomiting; in
some cases, symptoms of dysuria may be present. Complications include urosepsis,
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kidney damage and renal failure. Patients with pyelonephritis are treated with intravenous
antibiotics. All urinary infections that involve the upper tract, as well as those occurring
in patients with predispositions, such as indwelling catheters, cancer, calculi, anatomical
abnormalities, spinal cord injury, are considered complicated UTIs (Chiu, 2013).
Recurrent UTI is when an secondary infection follows another one which was clinically
resolved; it can be caused by the same bacteria as in the initial infection (relapse) or by a
different one (reinfection) (Salvatore et al., 2011). There are three approaches to
management: long-term, low dose antibiotics; a single antibiotic post-intercourse; or
three-day antibiotics in which the prescription has already been issued and the patient
self-diagnoses, starts the antibiotic and sends a urine sample for confirmation.
For symptomatic UTI, the first line treatment is an antibiotics (for example,
nitrofurantoin, fosfomycin, trimethoprim-sulfamethaxole, trimethoprim alone or a
fluoroquinolone) (Chu & Lowder, 2018), signs and symptoms tend to persist for at least
three days (Frimodt-Moller, 2002).
Some have considered targeting the symptoms, for example the pain by treating with an
analgesic such as ibuprofen. Clinical studies have shown that this approach can be as
effective as antibiotic treatment in uncomplicated UTIs (Bleidorn et al., 2010, 2016;
Franco, 2005), although it is not clear why a pain killer would interfere with
uropathogenesis as ibuprofen and its metabolites do not appear to have direct
antimicrobial activity (Whiteside et al., 2019). The main advantage is through providing
symptomatic relief within one day. This illustrates how approaches that target specific
signs and symptoms can play a role in disease management.

1.3

Malodour in the urogenital tract

Volatile compounds are produced as a part of the regular metabolism of humans, plants,
fungi and bacteria. Microbial associated diseases tend to be identified by specific smells
which, in many cases, are caused by volatile organic compounds (Thorn & Greenman,
2012). These compounds are the result of microbial metabolism, and they can include fatty
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acids, terpenoids, aromatic compounds, nitrogen containing compounds (e.g. amines), and
volatile sulfur compounds (Schulz & Dickschat, 2007).
Biogenic amines are basic nitrogenous compounds that have been correlated with BV,
particularly, cadaverine, putrescine, tyramine, trimethylamine (TMA). These compounds
are known causes of malodour (Borgogna et al., 2021; McMillan et al., 2015; Nelson et
al., 2015). Until now, the cause of malodour during a UTI was not been well established.
With the exception of TMA, none of the biogenic amines previously described for BV
had been correlated with UTI (Lam et al., 2014). Nonetheless, since both conditions are a
direct result of dysbiosis of the urogenital tract, we considered it likely that the
malodorous metabolites found in BV would also present during a UTI.

Figure 1.3 Biosynthesis of TMA and TMAO
One compound, TMA, which has a characteristic fishy smell, is a mammalian/microbial
co-metabolite that is produced by bacterial reduction of the mammalian-derived
trimethylamine N-oxide (Figure 1.3; Lam et al., 2014, 2015). Tyramine is produced via
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the decarboxylation of tyrosine by uropathogens such as Enterococcus faecalis
(Whiteside, 2018). Cadaverine is mostly produced by bacteria, such as E. coli, via the
decarboxylation of lysine (Watson et al., 1992). Putrescine is produced by bacteria and
human cells through the metabolism of ornithine or agmatine (Tabor & Tabor, 1985;
Tofalo et al., 2019).
Increased concentrations of tyramine, putrescine, and tyramine are associated with a
higher risk of transition from a L. crispatus-dominated vaginal microbiota to one with
lower abundance of this species. The mechanism appears to be biosynthesis that
consumes protons, and thereby increases the pH of the environment. Furthermore,
biogenic amines have been found to reduce the production of lactic acid and to slow
down the growth of several vaginal Lactobacillus species. This suggests that these
amines play a direct role in diminishing the Lactobacillus-mediated protection and makes
the environment more favourable for pathogens (Borgogna et al., 2021; Nelson et al.,
2015).

Figure 1.4 Biogenic amine biosynthesis increases the pH of the vaginal environment
(adapted from Nelson et al., 2015)
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1.4

Probiotics for female urogenital health

The emergence of a new field of science is exciting, yet invariably faces challenges to its
validity and acceptance of its scope of influence. This is certainly the case for probiotics,
defined as “live microorganisms that, when administered in adequate amounts, confer a
health benefit on the host”(FAO/WHO Working Group, 2002; Hill et al., 2014).
An early observation of the role that beneficial bacteria play in health was made by Elie
Metchnikoff in 1905. He proposed that the reason behind increased longevity in the
Bulgarian population was due to the lactobacilli used to produce a yogurt commonly
consumed in that region, and not the product itself as it was previously believed
(Metchnikoff, 1908). Nonetheless, although these findings set the grounds for research on
potential beneficial microorganisms, it was not until many decades later that formal
research of probiotics begun.
Prior to the early 2000’s, most microbiology studies related to humans were focused on
pathogenic organisms. After 2001, there was a significant increase in the endogenous
microbes of the human body and a belief that they could be determinants of health
(Relman, 2002; Relman & Falkow, 2001). When the Human Genome Project was being
carried out, it was deemed that for it to be sufficiently relevant, there had to be an
understanding of the relationship between humans and their microorganisms (Davies,
2001). This was a precursor for the Human Microbiome Project (HMP) and Metahit
Consortium which would compile an inventory of microbial organisms and their
genomes in the mouth, gut, vagina, and skin (but not bladder) of a healthy human cohort
(Peterson et al., 2009; Qin et al., 2010).
The introduction of a definition of probiotics was followed a year later by the
establishment of the International Scientific Association for Probiotics and Prebiotics
(ISAPP) in 2002 (Reid et al., 2003). This was a major factor in stimulating and focusing
research in this area and emphasizing the importance of scientific rigour and production
standards for probiotics. This has been reflected in peer-reviewed publications which
have increased substantially on the scientific database PubMed from just over 1,000 in
2002 to over 33,000 today (July, 2021). The breadth of the definition was intentional to
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allow capture of a range of host benefits. Subsequently, other terms have emerged such as
psychobiotics, next-generation probiotics, baby-biotics, but none adequately defined or
sufficiently different that they would fall outside the existing probiotic definition. These
terms seem to group probiotics in very specific clusters, with very definite uses, when in
reality most of the probiotic strains available will have more than one targeted benefit on
the host. Therefore, such terminology is confusing to healthcare providers, producers and
consumers.
The increase in products termed ‘probiotic’ on the market does not necessarily equate
with a reason to celebrate successful translation of science to commerce and consumers.
Too many products fail to comply with the characteristics required to be called probiotic.
Many false claims and rampant misuse of the term has resulted in mainstream consumer
channels providing incorrect information to consumers.
Probiotics are not inside us, not in fermented food, not necessarily better if there are more
species or a higher viable count. Too many formulations are being concocted not based
on research evidence, but on marketing and what might appeal to consumers. For
example, products are being composed supposedly to improve vaginal health using
strains not documented to compete with urogenital pathogens, improve immunity or do
anything that can restore homeostasis to that region of the body. In other words, there are
no data to support their selection. Yet, the internet, the use of words to reach the first
page of search engines and use of pseudo-experts for promotion provide a means for
these products to be highly rated and appear to be the best clinically documented for
preventing or curing bacterial or yeast infections in the vagina.
The net result is misleading and confusing to consumers as well as making healthcare
professionals leery of the whole field of probiotics. To counter this, we need to re-state
important facts.
For a product to be considered probiotic, it must comply with three core characteristics:
(1). The strain(s) must be characterized, including genetically and phenotypically and a
rationale given based on documented experiments published in peer-reviewed papers, for
their inclusion for the intended use. (2). The product must contain sufficient live
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microorganisms at time of use that are equivalent to when the product was shown in
clinical studies to confer a benefit to the desired target site. (3). The delivery method,
dosage and length of use should be based on scientific evidence in humans if they are the
intended recipient.
It makes it difficult for consumers if the product label does not state strain designations
because it becomes impossible to track the research performed on the contents. Dosages
are rarely stated on labels, and some products only contain filtered extracts or ferments or
lysed bacteria, meaning that no live microorganisms are present: thus, the product is not
probiotic, and the term should not have been used.
The lack of effective treatment options for urogenital conditions such as BV and UTI has
increased the interest in probiotic research as a tool to address this problem (Bilardi et al.,
2013; Tandogdu & Wagenlehner, 2016). Clinical observations by urologist Andrew
Bruce in 1973, set the wheels in motion for considering lactobacilli as probiotics for the
urogenital tract of women (Bruce et al., 1973; Bruce & Reid, 1988). While the rest of the
field was trying to develop vaccines and therapies against uropathogenic E. coli, none of
which have so far borne fruit, he believed that replenishment of lactobacilli into the
vagina where E. coli were dominant after repeated UTIs and antibiotic treatments, might
restore homeostasis and protect the host.
Probiotics can be used to replenish organisms that are naturally in each niche but whose
numbers have been depleted and illness has occurred. For example, administering
Lactobacillus crispatus into the vagina to counter BV or ascension of uropathogenic E.
coli into the bladder (Stapleton et al., 2011). But optimally, probiotic strains should be
selected for their properties not their origin. These can include the ability to counter
pathogens/conditions causing illness, with the aim being to restore health and ideally
allowing the indigenous beneficial microbes to return. The example would be to orally
administer Lacticaseibacillus (formerly Lactobacillus) rhamnosus GR-1 (LGR-1) and
Limosilactobacillus (formerly Lactobacillus) reuteri RC-14 (LRC-14), which are not
species highly prevalent in the vagina, but whose administration results in recovery from
infection and the return of indigenous L. crispatus and L. iners (Macklaim et al., 2015).
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Inspired by the LGR-1/LRC-14 studies, a number of probiotic strains have been
developed to prevent urogenital infections, Lactobacillus acidophilus A-212,
Lacticaseibacillus rhamnosus A-119, with Streptococcus thermophilus A-336; L.
rhamnosus PBO1 with Lactobacillus gasseri EN-153471 (EB01); and L. rhamnosus
Lcr35 in vaginal ovules. Strains LGR-1 and LRC-14 are the only ones approved for oral
use in Canada and the United States. The positive early clinical studies performed with
LGR-1 and LRC-14 showing improved vaginal microbiota and reduced infection
recurrence (Reid, 2017), have been confirmed by others (Beerepoot et al., 2012;
Petricevic et al., 2008; Vujic et al., 2013). The mechanisms of action include an increased
ascension of probiotic and indigenous lactobacilli from rectal skin to the vagina, reduced
pathogen ascension, localized inhibition and displacement of pathogens, and priming of
antimicrobial defences (Karlsson et al., 2012; Reid et al., 2011). Anti-fungal effects have
also been reported coinciding with improved curing of VVC (Köhler et al., 2012;
Martinez et al., 2009).
The vaginal administration of probiotic Lactobacillus began in the late 1980s (Bruce &
Reid, 1988), and has since led to other strains being tested for urogenital health including
L. crispatus CTV05 to prevent recurrence of UTI (Stapleton et al., 2011), L. rhamnosus
IMC 501 with , L. paracasei IMC 502 (Verdenelli et al., 2016b) for vaginal health, L.
rhamnosus Lcr35 to aid in the management of BV and VVC (Petricevic & Witt, 2008;
Rossi et al., 2010), and L. gasseri EN-153471 (EB01) to help treat BV in conjunction
with antibiotics (Larsson et al., 2011).
A study of the genome of LGR-1 showed that it is better adapted to the vagina than the
most commonly used intestinally-derived probiotic L. rhamnosus GG, by having a unique
cluster for exopolysaccharide production, metabolizing lactose and maltose, and to better
withstand oxidative stress (Petrova et al., 2018).
Probiotic strains have been shown to reduce oral malodorous compounds. For example,
Streptococcus salivarius K-12, administered after an antimicrobial mouthwash, was
shown to reduce levels of volatile compounds, as measured by a halimeter and changes in
the bacterial composition of the participants’ saliva (Burton et al., 2006). Results showed
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a decrease of more than 100 ppb in the concentration of malodourous compounds after 7
days. Moreover, S. salivarius K12 was still detected after a week of instillation, and the
growth of halitosis causing bacteria was suppressed. A similar approach could be used for
the reduction of malodorous compounds in the female urogenital tract.
Previous studies have reported that certain lactobacilli strains can degrade biogenic
amines. Although these results correspond mainly to strains relevant to the food industry
and not to human health, they prove that there are Lactobacillus strains with this capacity
(Niu et al., 2019; Zhang et al., 2021).
Lactobacillus-mediated reduction of biogenic amines can be a result of inhibiting the
bacterial species that produce them, or it can be mediated by amine oxidase activity.
These are enzymes that can be divided in two subfamilies depending on their cofactors.
The amine oxidases family that contain copper as their cofactor is divided into three
subclasses: diamine oxidase, primary-amine oxidase, and diamine oxidase. These
enzymes catalyze the oxidative deamination of biogenic amines (Cona et al., 2006;
Grimsby et al., 1991; Levering et al., 1981; Niu et al., 2019; Tipton et al., 2012).
Unfortunately, the specific pathways and enzymes used by lactobacilli to degrade amines
are still not well characterized, but their potential for this use is clear.
Vaginal administration of probiotic Lactobacillus using suppositories has already been
tested for efficacy and safety. A clinical study were healthy women received the
commercially available probiotic suppositories SYNBIO® gin (containing L. rhamnosus
IMC 501 and Lacticaseibacillus paracasei IMC 502), demonstrated that the treatment
was well tolerated and there were no reports of side effects. Furthermore, an increase in
the lactobacilli level of the participants was observed (Verdenelli et al., 2016a). The fact
that probiotics have been successfully and safely applied in a direct manner, indicates that
their topical application could be an effective mean of delivery in the treatment of
urogenital tract infections in women.
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1.4.1

Topical use of probiotics for urogenital applications

This section contains segments adapted and reproduced with permission (Appendix B)
from: Puebla-Barragan S, Reid G. Probiotics in cosmetic and personal care products:
trends and challenges (2021). Molecules, 26,1249. Supplemental material available for
download at: https://www.mdpi.com/1420-3049/26/5/1249
The increased interest in microbes colonizing the human body, not simply those infecting
it, has led to many studies attempting to manipulate the microbiome in a given niche, in
favour of health. The use of beneficial microbes for this purpose has seen the field of
probiotics grow substantially. This includes personal care applications, where the market
for probiotics is projected to grow at a 12% rate in the next ten years, with North America
the driver (FactMR, 2020).
The topical delivery of probiotics is an emerging area principally used for the treatment
of skin disorders. Specifically, several lactobacilli strains have been shown to have the
capability of efficiently adhering to the keratin on the skin, where they express
antimicrobial capabilities against pathogens and prevent biofilm formation (Lopes et al.,
2017). Of importance, some topical formulations have been able to preserve the viability
and probiotic capabilities of the bacteria (Mehdi-Alamdarloo et al., 2016).
As previously stated, a healthy vaginal environment is in most cases populated by an
abundance of lactobacilli. Various triggers, from use of douches and antibiotics to
multiple sexual partners and influx of pathogens into the area, can disrupt the
homeostasis giving rise to BV, UTI, VVC and other inflammatory and irritant conditions.
This provided a rationale 48 years ago to supplement the urogenital tract with lactobacilli
to restore a healthy state (Bruce et al., 1973; Puebla-Barragan & Reid, 2019). Since then,
the vaginal administration of probiotic strains of Lactobacillus through suppositories or
ovules has been explored (Bruce & Reid, 1988).
Given the significant negative impact of antimicrobial therapy on the urogenital
microbiota and failure to restore homeostasis, probiotic strains have been used in
combination to help with recovery. These include L. gasseri EN-153471 (EB01) for the
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management of BV (Larsson et al., 2011) and LGR-1 plus LRC-14 in combination with
antibiotics or anti-fungals (Anukam et al., 2006; Martinez et al., 2009; Vujic et al., 2013).
Additional strains have become available in the American market with minimal clinical
and scientific documentation (Skokovic-Sunjic, 2021). The supplements are believed to
function through ascension from the rectal skin to the vagina, where they reduce
pathogen ascension and inhibit and displace pathogens while also conferring
antimicrobial defences through the production of bioactive compounds such as lactic acid
and bacteriocins.
Therefore, these are essentially cosmetic in action because the skin is the surface of
interaction. These products are regulated as drugs or natural health products with
functional and structural or even disease risk reduction claims. The application of strains
directly into the vagina using suppositories is approved in Canada. Elsewhere, products
are being delivered through coating tampons and pomades (Handalishy et al., 2014;
Sauperl et al., 2020), but further evidence is required to confirm they are probiotic and
benefit the host. The development of topical gel containing probiotic lactobacilli is being
pursued, with promising preliminary results for treating VVC (Donders et al., 2020).
The potential for probiotic strains to reduce urogenital malodour has not been well
investigated (Bilardi et al., 2013). Many non-probiotic products such as vaginal douches,
vinegar rinses, and fragrances claim to help reduce malodour. However, their efficacy is
dubious and they can increase the risk of infection, including sexually acquired through
disruption of the beneficial microbes (Brotman et al., 2008; Fashemi et al., 2013). An
advantage of an effective probiotic would come from its ability to grow and produce
metabolites that degrade or neutralize malodorous compounds (McMillan et al., 2015;
Puebla-Barragan et al., 2020). Depending on the nature of such a product, it may have to
be registered as an over-the-counter (OTC) drug and not as a cosmetic or personal care
product.

1.5

Knowledge gaps

Urogenital dysbiosis is a complex phenomenon which is not yet fully understood.
Likewise, the role of microbial metabolites and their effects in disrupting or maintaining
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homeostasis require more investigation. This thesis aims to fill some of these gaps and
make a connection between the metabolome and the microbiota.
To date, most of the focus has been in characterising the communities in the vaginal
microbiome, without enough emphasis on why they are there and what are they doing.
Long-held unproven concepts are being questioned, for example with the finding that few
lactobacilli strains can break down glycogen to use it as a nutrient source (van der Veer et
al., 2019).
Current diagnosis of BV and UTI leading to the instigation of treatments has not changed
for over forty years. In essence, this comprises broad spectrum antibiotics to try and
eradicate certain pathogens. It is far from ideal due to non-specific killing of commensals,
drug resistance development by pathogens and failure to treat specific patient complaints,
such as malodour. Prior to the beginning of this doctoral project, the causes of malodour
during UTI were understudied, and their correlation with vaginal malodour was
overlooked.
In order to understand pathogenesis and health, studies are needed to examine the strains
present, those being administered as probiotics, and the products they produce. This
requires metabolomic applications that will be described below.

1.6
1.6.1

Approaches for filling the knowledge gaps
Use of metabolomics and multivariate statistics

The low molecular weight products of cellular processes are known as metabolites.
Organisms produce them due to genetic or environmental changes. The set of metabolites
synthesized by a biological system is its metabolome (Fiehn, 2002). Metabolomics is the
comprehensive identification and quantification of all metabolites in a biological system
produced as a response to biological processes (Dettmer et al., 2007). Metabolomics
studies look at ‘which’ metabolic pathways are active and functional in an organism.
Different ‘omics’ techniques complement each other by answering different questions.
While genomics looks at what can happen, transcriptomics at what appears to be
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happening, and proteomics at what makes it happen, metabolomics links genotypes and
phenotypes by investigating what has happened (Dettmer et al., 2007; Fiehn, 2002).
Targeted metabolomics looks for specific compounds and uses authentic standards to
confirm the identity of the analytes. Therefore, the sample preparation protocol has to be
designed to specifically retain the metabolites of interest (Dettmer et al., 2007; Fiehn,
2002). This allows to measure specific responses of organisms. This approach can be
quantitative and isotopically labelled standards can facilitate metabolite detection.
Nonetheless, coverage of the metabolome is limited, increasing the odds of overlooking
the metabolomic response of interest (Ribbenstedt et al., 2018).
Untargeted metabolomics aims to detect as many metabolites as possible and, relying on
multivariate statistics, it can identify novel biomarkers and global differences between
groups. Since untargeted metabolomics looks for global differences, sample preparation
is simpler and is done by only removing salts or large peptides and proteins that could
interfere with the analysis (Dettmer et al., 2007; Fiehn, 2002). One of the main
limitations of untargeted analyses is the detection of unknown compounds (Sindelar &
Patti, 2020). Although methods are being developed to improve this, it remains a major
bottleneck of the workflow (Roberts et al., 2012; Wang et al., 2019; Zhou et al., 2020).
Furthermore, since it is not a quantitative approach, the identification of baseline
metabolite levels is more complicated than in targeted metabolomics (Ribbenstedt et al.,
2018).
Ultimately, the selection of an approach will depend on the research question. In many
cases, both approaches are used to complement each other and yield a more
comprehensive overview of the diverse metabolic processes taking place in a given niche
– in our case, the urogenital tract.
Metabolomic analyses are commonly performed to identify differences in metabolite
abundances through comparative experiments (Fiehn, 2002). Since analytes have diverse
physicochemical properties and are present at different concentrations, each protocol
must be designed to properly identify the metabolites of interest. As such, designing an
appropriate methodology that suits the analytes of interest and that objectively answers
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the research question is critical. Ideally large sample sizes increase statistical power and
detect biologically relevant sample clustering, but this is not always feasible. After
experimental design, the workflow generally begins with the sample collection, followed
by storage and pre-processing samples in a way that minimizes the formation or
degradation of metabolites due to enzymatic or oxidation processes (Dettmer et al., 2007;
Fiehn, 2002).
The next stage is sample preparation, which might include the addition of an internal
standard as well as the extraction of the analytes of interest. When working with complex
biological matrices (i.e. serum, plasma, urine, whole blood, saliva, or culture media) it is
important to bring them into a form compatible to the analytical technique, while also
removing matrix components that could cause interference. (Dettmer et al., 2007; Fiehn,
2002).
Sample preparation is followed by a separation step, which is normally carried out using
either liquid (LC) or gas (GC) chromatography, although the former is the most common
technique used in metabolomics and was the one used throughout this thesis (Ribbenstedt
et al., 2018). In liquid chromatography, separation is commonly performed via high
performance liquid chromatography (HPLC), which is based on the separation of
compounds based on their size and polarity. For this purpose, the sample is injected into a
column which will act as the stationary phase. Often C18 columns are used to perform
reverse-phase chromatography, in which the stationary phase is hydrophobic, and the
mobile phase is hydrophilic. In practical terms, this means that hydrophobic or less polar
compounds will be retained by the column and the mobile phase will cause their elution.
The opposite is known as normal-phase chromatography, in which a hydrophilic
stationary phase is used: such as a hydrophilic interaction chromatography (HILIC). In
this case, polar compounds are retained due to higher affinity to the column, and a nonpolar mobile phase is used for their elution. This is ideal for the separation of highly polar
molecules such as amines and amino acids (Dettmer et al., 2007; Roberts et al., 2012;
Sindelar & Patti, 2020; Theodoridis et al., 2013).
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Next, sample analysis is carried out, mostly by specialized detecting technologies such as
nuclear magnetic resonance (NMR) or tandem mass spectrometry (MS/MS), although the
former requires more specific technical skills and can be more expensive (Fiehn, 2002;
Forcisi et al., 2013; Theodoridis et al., 2013).
Most HPLC instruments are equipped with an UV detector, which uses absorbance to
detect the eluting molecules. However, the applications for this technique are limited and
normally used for simpler analyses or as a complement to other metabolomic methods
(Bélanger et al., 1997).
In targeted approaches, analysis and quantification are usually carried out with
specialized software provided by the manufacturers of the analytical instrument, or with
open source platforms (Wenig & Odermatt, 2010). Given the high-throughput nature of
untargeted metabolomics, multivariate analyses are required. Amongst the most used are
principal component analysis (PCA) and partial least squares projection to latent
structures (PLS).
Multivariate analyses allow projecting the data in more than two dimensions, allowing
identification of similarities and clustering between samples. These tools help to
differentiate between classes in complex data sets (Long, 2013; Worley & Powers, 2013).
The final step is the identification of relevant metabolites, which can then be used for
further targeted analyses (Fiehn, 2002; Roberts et al., 2012; Theodoridis et al., 2013). The
output will depend on the instrument used. For instance, when working with MS/MS the
variables used to identify each compound are the retention time (RT), the exact mass
(m/z), and the fragmentation pattern of the molecule. These outputs are then matched
with authentic standards (in targeted studies) or with the use of databases, such as
METLIN, that compiles theoretical and experimental data on the spectra of the most
common metabolites (Smith et al., 2005). A summary of a typical metabolomic study
workflow is shown in Figure 1.4.
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Figure 1.4 Workflow of a metabolomics study

1.6.2

Identifying lactobacilli that degrade biogenic amines

As mentioned above, it is critical to select probiotic strains based on the characteristics
required and intended use. Unfortunately, the rationale is simply whether a species is
commonly found.
We recently collaborated with a Dutch group to investigate L.crispatus strains from
healthy women and those with a history of BV. The hypothesis was that the strains from
healthy women would be different genetically and phenotypically from those isolated
from women who had suffered from infection, because presumably these strains were not
protective. However, the results did not support the hypothesis and subject of origin was
not predictive of their properties, emphasizing that candidate probiotic strains cannot
simply be by isolating ones from healthy subjects.
With access to these strains, we were presented with the opportunity to examine the
metabolic profiles and investigate whether these or other strains could degrade biogenic
amines.
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1.7

Project scope and relevance

Hypothesis: Pathogenic bacteria in the urogenital tract produce biogenic amines, and
lactobacilli can reduce their concentration.
Objectives:
(i)

Identify malodorous compounds formed during UTIs. In Chapter 2 we used
untargeted and targeted metabolomics to evaluate urine samples from women with
an active UTI. We also explored the in vitro ability of uropathogenic strains of E.
coli to produce biogenic amines in female urine. We identified that the malodorous
amines trimethylamine, cadaverine, and putrescine are elevated in UTI conditions.
This approach was novel given that malodour in UTIs is a sign that has been often
overlooked.

(ii)

Identify biochemical characteristics in Lactobacillus crispatus strains that
make them good probiotic candidates. Chapter 3 focuses on the metabolomic
profiling of clinical isolates of L. crispatus. We confirmed that strains sourced
from healthy patients did not have a specific metabolomic or genomic profiles
that differentiate them from those isolated from dysbiotic vaginal environments.
We also identified that strains from dysbiotic environments showed higher
antimicrobial activity towards common urogenital environments, suggesting that
L. crispatus adapt to their environment by developing traits that might aid them
survive stress exposure.

(iii)

Identify lactobacilli strains with malodour-degrading activity and
characterize their interaction with biogenic amines. In Chapter 4 we tested if
commensal and/or probiotic bacteria can degrade biogenic amines. We
successfully characterised several strains with this ability. We also identified that
cell-free supernatants could retain this activity. These findings open major
opportunities for the development of odour-degrading products for the urogenital
tract either through the use of probiotics or with the use of their metabolites.

(iv)

Evaluate probiotic bacteria compatibility with oils safe for human use. With a
view to developing a practical treatment for women, oils safe for human use (i.e.
coconut oil, olive oil, petroleum jelly, and mineral oil) were used in Chapter 5 to
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test survival rates of a freeze dried commercial blend of the probiotics LGR-1 and
LRC-14. Such vehicle could be used to deliver different strains and by-products
to provide the recipient with rapid relief from malodour while also aiding in
restoring urogenital homeostasis. Specifically, we identified coconut oil and
petroleum jelly as ideal candidates for this purpose. Our findings provide valuable
information on the potential of malodour-degrading lactobacilli to be
implemented in a topical treatment.
Both UTI and BV are highly prevalent health problems. Major discomfort is caused by
the malodour that these conditions cause, which has a significant impact in the quality of
life of women. This project will help to better understand the probiotic capabilities of
lactobacilli in the female urogenital tract. Specifically, how they can be used to target
malodour. This is a valuable approach in terms of conjoint treatment (along with
antibiotics and/or pain-relieving agents) of women with BV and UTI. These observations
are of great significance, given that the current line of treatment, with antibiotics, is not
efficient. Therefore, if probiotics could be used to target specific symptoms, and in this
way, improve the way these conditions are managed, the impact on the quality of life of
patients would be very significant.
The proof-of-concept in terms of their use in an oil-based formulation for topical delivery
will provide the basis for further studies in which novel formulas optimize their viability
and retain their activity. This approach also has many potential applications by
combining different microorganisms in one chamber and different substances in the
other. This concept can be of great value as it is an approach that can be applied to
alleviate other microbiome-influenced conditions that can be treated topically (e.g.
disorders caused by skin dysbiosis).
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2.1

Abstract

Many women suffer from urinary tract infections (UTIs). In addition to pain and
increased urgency to urinate, malodour is a major issue for these patients. The specific
factors causing this malodour are unclear, and there are no targeted treatment options to
counteract it effectively. We used a metabolomics approach to compare the chemical
composition of metabolites in the urine of women with E. coli UTIs (n = 15) and those
who are healthy (n = 10). The biogenic amines trimethylamine and putrescine, which
cause malodour in other urogenital conditions, were significantly increased in UTI
patients. Conversely, the precursor of trimethylamine, trimethylamine N-oxide, was
lower. To further confirm the source of the malodorous compounds, in vitro experiments
were conducted by incubating strains of uropathogenic E. coli in sterilized urine from
healthy women. All tested strains accumulated trimethylamine and putrescine. Notably,
cadaverine was also produced by E. coli strains in vitro; however, it was not significantly
different between both groups. This study identifies the origin of urogenital malodour in
women with UTIs.
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2.2

Introduction

Urinary tract infections (UTIs) are a highly prevalent global health problem, with over
50% of women expected to experience at least one in their lifetime (Foxman, 2003;
Tandogdu & Wagenlehner, 2016). Lower UTIs are more common than those infecting
the kidney, and Escherichia coli (UPEC) strains are responsible for approximately 80%
of the cases. These uropathogens originate from the gastrointestinal tract (Salvatore et al.,
2011) and enter the bladder via the fecal-vaginal-periurethral route (Moreno et al., 2008).
These infections are present with dysuria, increased frequency of urination, abdominal
pain, and malodour (Sj et al., 2004). However, besides ammonia, which is a known cause
for foul-smelling urine (Forsgren-Brusk et al., 2017; Norberg et al., 1984), other sources
of malodour during infection and the source of their production require further
characterization. None of the currently available treatment regimens target malodour. A
better understanding of the chemical origins of malodour during this condition would
enable the creation of more targeted and efficient therapies.
Biogenic amines are basic nitrogenous compounds with well-established organoleptic
characteristics (Table 2.1) associated with malodour (Nelson et al., 2015). Most of them
are biosynthesized from amino acids, as shown in Figure 2.1. Trimethylamine (TMA),
tyramine, cadaverine, and putrescine are of interest since they are known causes of
urogenital malodour in conditions such as bacterial vaginosis (BV) (McMillan et al.,
2015; Nelson et al., 2015). Until now, these compounds have not been associated with
urinary malodour, except for trimethylamine (TMA), which has a characteristic fishy
odour and was previously proposed as a candidate biomarker for E. coli-associated UTI
(Lam et al., 2014). It is a mammalian/microbial co-metabolite since the production of
TMA by bacteria depends on the reduction of mammalian-derived trimethylamine Noxide (TMAO) (Lam et al., 2014, 2015).
Tyramine is synthesized via decarboxylation of tyrosine, and it is produced by
uropathogens such as Enterococcus faecalis (Whiteside, 2018), but it has not been
reported in UPEC strains. Cadaverine, which is primarily a bacterial metabolite (Tofalo et
al., 2019), is the product of the decarboxylation of lysine, and it is thought to be
synthesized by E.coli in anaerobic and low pH conditions (Watson et al., 1992).
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Putrescine, produced both by human and bacterial cells (Tofalo et al., 2019), is a product
of amino acid catabolism (Tabor & Tabor, 1985), either from ornithine or agmatine, the
latter being a product of the decarboxylation of arginine (Figure 2.1).

Figure 2.1 Biosynthetic origin of biogenic amines
Each arrow represents a single reaction catalyzed by the described enzyme.
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Table 2.1 Odour characteristics of biogenic amines
COMPOUND

ODOUR DESCRIPTION

ODOUR

ODOUR

DETECTION

STRENGTH

THRESHOLD
Trimethylamine

Fishy/oily/rancid/sweaty/fruity(The Good

0.000032 ppm

Very high

Scents Company, n.d.-a)

(Leonardos et al.,

(The Good

1969)

Scents
Company,
n.d.-a)

Tyramine

Mild/meaty/dirty/cooked/phenolic/rubbery (The NA

Moderate

Good Scents Company, 2006)

(The Good
Scents
Company,
2006)

Cadaverine

Putrescine

Sperm/dead-animal/animalic (The Good Scents 190 ppm (Wang et NA
Company, n.d.-b)

al., 1975)

Animal/rotting/fish (The Good Scents

22 ppm (Wang et

Company, n.d.-c)

al., 1975)

NA

It has long been hypothesized that some of these compounds play an important role in
pathogenesis. For instance, entero-invasive strains of E. coli are unable to produce
cadaverine, a compound that interferes with the invasive process (Maurelli et al., 1998).
While putrescine enhances survival within oxidative environments (Campilongo et al.,
2014) and augments cell growth and proliferation (Igarashi & Kashiwagi, 2018).
Consistent with these observations, Satink et al. showed that putrescine levels increased
in patients with UTI before antibiotic therapy, then decreased as a result of the treatment,
presumably because the producers were eradicated (Satink et al., 1989). However, no
differences were detected for cadaverine in either case, likely because urinary cadaverine
is primarily derived from the gastrointestinal microbiota and dietary sources (Tofalo et
al., 2019).
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It has been reported that cadaverine production increases when UPEC strains are grown
under nitrosative stress, potentially conditioning them for enhanced colonization of the
host (Bower et al., 2009; Bower & Mulvey, 2006). This is of relevance since, during a
UTI, there is a significant formation of nitric oxide and reactive nitrogen intermediates
(Carlsson et al., 2001; Wheeler et al., 1997). Nevertheless, the specific role of cadaverine
in resistance to nitrosative stress is unclear. Potentially, during an infection UPEC strains
produce a significant amount of cadaverine, which would, in turn, cause malodorous
urine. Yet, previous work has shown no change in cadaverine levels during UTI (Satink
et al., 1989).
The present study aimed to take a metabolomics approach to identify molecules
responsible for urinary malodour and their biosynthetic origins.

2.3
2.3.1

Materials and Methods
Urine samples collection and processing

For in vitro testing purposes, mid-stream urine samples were collected from three healthy
pre-menopausal women (age 20-40). These were centrifuged at 4500 x g for 10 min to
remove any solid particles, followed by filter-sterilization using 0.22 µm syringe filters.
To ensure asepsis, 10µL of urine were plated on LB plates. To determine hydration
levels, and for normalization purposes, creatinine concentration was quantified using the
Creatinine (urinary) Colorimetric Assay Kit (Cayman Chemical Co., Ann Arbor, MI,
USA) as described by the manufacturer. Hydration levels were determined according to a
validated 8-scale urine colour chart (Armstrong et al., 1994; Rolker et al., 2017).
Creatinine levels were used to adjust the concentrations of the metabolites present in the
sample as it is an indicator of the hydration levels of the patient, hence allowing to adjust
for potential variability in the overall dilution of the urine output.
Thirty-one urine samples from women with UTI were provided by Dr. Ana Cabrera from
the Division of Microbiology at the Pathology and Laboratory Medicine Centre of
London Health Sciences Centre (London, Ontario, Canada). None of the patients were
identified to the study group. These samples included 10 UTI-negative controls and 21

46
samples from patients clinically diagnosed with a UTI, from which 15 were positive for
E. coli, 3 for Staphylococcus aureus, 2 for Klebsiella pneumoniae, and 1 for
Pseudomonas aeruginosa. Diagnosis criteria were based on the presence of signs and
symptoms and significant bacteriuria (bacterial growth ≥105 colony-forming units
(CFU)/mL). To further characterize the samples, pH was measured using test strips and
creatinine was quantified. Figure 2.2 shows a linear correlation between both methods
used to determine hydration levels.
All urine samples were obtained in accordance to article 2.4 of the Tri-Council Policy
Statement: Ethical Conduct for Research Involving Humans – TCPS 2 (2018).

Figure 2.2 Validation of the methods used to measure hydration levels
The dashed red line indicates the mean creatinine level and the black line represents the median.
There is a positive correlation between the two methods (R2 = 0.7103).

2.3.2

LC-MS analysis of urine samples

Samples were prepared based on the methodology proposed by Spagou et al., 2011.
Briefly, aliquots of 250 µL were taken of each urine culture and diluted with pure
methanol (1:3 for clinical samples and 1:6 for the in vitro analysis), vortexed, incubated
on ice for 30 min, and centrifuged at x16000g for 10 min. Supernatants were then filtered
using 0.22 µm PTFE syringe filters and added to vials for analysis. Samples were

47
analyzed using a Q-Exactive Quadrupole Orbitrap MS, coupled to an Agilent 1290 HPLC
system with an Agilent HILIC-Z (2.1 × 100 mm, 2.7 µm; Agilent) column. Compounds
were resolved with mobile phases of 20 mM ammonium formate in water (A) and 20 mM
ammonium formate in 90% acetonitrile (B) operating with the following gradient: 0 min,
100% B; 0.5 min, 100% B; 5.3 min, 80% B; 9.5 min, 30% B; 13.5 min, 30% B, 14.5 min
100% B and 16.5 min, 100% B. The following conditions were used for heated
electrospray ionization (HESI): HESI(+) capillary voltage, capillary voltage, 3.5 kV;
capillary temperature, 250 °C; sheath gas, 30.00 units; auxiliary gas, 8.00 units; probe
heater temperature, 450 °C; S-Lens RF level, 60.00. The LC-MS was operated using a
top 3 data-dependent acquisition (DDA) experiment that involved a full MS scan in the
mass range of m/z 58-870 at 35,000 resolution, followed by MS/MS scans at 17,500
resolution, isolation window of m/z 1.2 and collision energy of 28. The biogenic amines
and amino acids quantified in the full MS scans were: cadaverine, putrescine, tyramine,
spermine, spermidine, histamine, TMA, phenylalanine, leucine, tryptophan, isoleucine,
methionine, valine, tyrosine, proline, alanine, threonine, glutamine, serine, asparagine,
glutamic acid, aspartic acid, histidine, arginine, cystine, lysine, ornithine, glycine, and
TMAO. The standards used for calibration curves were acquired from Sigma Aldrich (St.
Louis MO). TMAO was analyzed semi-quantitatively using the log transformation of its
peak area (Figure S7).

2.3.3

Uropathogenic Escherichia coli cultures

A time-course analysis was performed using clinical UPEC strains GR-12, IA2, 536 and
J96, to assess whether there is a significant difference in polyamine production amongst
strains over time. All the strains used were clinical isolates from patients with acute UTI
(Clegg, 1982; Edén et al., 1982; Hull et al., 1981; Müller et al., 1983). Samples were
prepared by inoculating pooled urine (from three healthy females) with UPEC and
incubated aerobically for 24 h at 37ᵒ C; aliquots were taken at 0h, 3h, 6h, 9h, 12h, and
24h, and analyzed through HILIC-MS, post-acquisition recalibration was performed to
the results and the concentrations of the metabolites of interest was quantified. Growth
was monitored measuring optic density at a wavelength of 600 nm to ensure uniform
growth of the strains.
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2.3.4

LC-MS Data analysis

Proteowizard (Chambers et al., 2012) was used to convert the Thermo .raw files to.mzml
format, with peak peaking filter applied. Features were detected using the XCMS
package (Benton et al., 2010; Smith et al., 2006; Tautenhahn et al., 2008) with the
centWave (Tautenhahn et al., 2008) method (ppm tolerance 1.0). The signal to noise
threshold was set to 5, the noise was set to 3×106 and pre-filter was set to six scans with a
minimum 5,000 intensity. Retention time correction was conducted using the obiwarp
(Prince & Marcotte, 2006) method. Grouping of features was set to those present in at
least 25% of all samples (retention time deviation 10 s; m/z width, 0.015). The ‘fillPeaks’
function with default settings. Remaining zeros values were imputed with two thirds the
minimum value on a per mass basis. Large mass salt clusters and ionization artifacts were
filtered using the McMillan correction (McMillan et al., 2016). For the targeted analysis,
Xcalibur (Thermo Scientific, Waltham, MA) was used to quantify the metabolites of
interest. Compounds were identified by accurate mass, comparison of retention times to
authentic standards or by accurate mass and comparison of fragmentation patterns to
MS/MS databases (Smith et al., 2005).
The data generated were submitted to the EMBL-EBI MetaboLights database with the
identifier MTBLS1294 (https://www.ebi.ac.uk/metabolights/MTBLS1294) (Haug et al.,
2013).

2.3.5

Statistical analysis

RStudio version 1.2.1335 was used for all statistical analyses. Plots were generated with
the ggplot2 package (Wickham, 2009). For the untargeted metabolomics analysis, the
FactoMineR package with Pareto scaling was used to perform a PCA (McMillan et al.,
2016). Targeted metabolomics comparisons in the clinical samples were analyzed using a
two-sample two-tailed t-test analysis and defined a p-value of ≤0.05 as statistically
significant. Time-course trials were analyzed using a linear mixed-effect model with
Tukey’s test for multiple comparisons and to control for type I error. Log transformation
was used to correct the distribution and heteroscedasticity of the data (Di Guida et al.,
2016).
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Results

2.4
2.4.1

Clinical sample characterization

In total, 31 human urine samples were obtained, comprising both of clinically defined
UTI-negative (n = 10) and UTI-positive (n = 21) samples. Of the latter, E. coli was the
dominant pathogen in 15 individuals, while Staphylococcus aureus, Klebsiella
pneumoniae, Pseudomonas aeruginosa were dominant in 3, 2 and 1 individuals,
respectively. There were no significant associations between UTI and urinary pH or
creatinine concentration (Supplementary Material, Figures S1, S2). Only samples positive
for E. coli were discussed in the subsequent results. Analyses of samples infected by
other pathogens can be found in the Supplementary section.

2.4.2

Metabolomics of UTI-positive clinical samples

The metabolomic profiles of the human urine samples were analyzed by high-resolution
LC-MS. Biogenic amines and other small polar compounds are not well suited for
chromatographic separation using a C18 reverse-phase column. Therefore, a hydrophilic
interaction chromatography (HILIC) approach was used (Figure 2.3).
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Separation carried out using HILIC chromatography, ideally suited for polar compounds (e.g.
biogenic amines and amino acids).

The features extracted by XCMS were analyzed using a principal components’ analysis
(PCA) model. No distinct grouping of samples could be observed in the 1st dimension.
However, separation of both UTI and healthy groups was observed in the 2nd and 4th
(27.2% total explained variance). The main compounds responsible for the separation of
these groups were TMA and TMAO (Figure 2.4).

Figure 2.4 TMA and its precursor TMAO are driving the separation between UTIpositive and negative samples in multivariate analysis
(A) Principal components analysis (PCA) score plot of Healthy (black, n=10) vs UTI-positive
samples (red, n=15), where each point represents a single sample from a single woman. The
location of each point displays differences in the metabolome, with samples closer to each other
being similar. Ellipses represent the 95% confidence intervals; (B) PCA loadings, which show the
weights of each metabolite in the principal component cartesian plane. Each point represents a
single metabolite. Biogenic amines, as well as their precursors, are colour coded.

Biogenic amines, as well as some standard amino acids, were also quantified in the
clinical urine samples. Following normalization with urinary creatinine concentrations,
both TMA and putrescine were significantly elevated between groups, whereas
cadaverine and tyramine were not (Figure 2.5).
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Figure 2.5 Comparison of the concentration of biogenic amines in Healthy vs UTI positive
patients
Control consists of the urine of healthy patients (n=10). TMA and putrescine levels are higher in
patients with UPEC caused UTI (n=15). Only the samples positive for UPEC were included in
this analysis. Black lines indicate the median and the red dashed lines represent the mean.
Significant differences were determined on log-transformed values using a two-sample t-test
(*p≤0.05).

The concentrations of the precursors of these amines are shown in Figure 2.6; only
TMAO—which yields TMA—was significantly lower in UTI patients. On the amino acid
analysis, aspartic acid and glutamic acid were significantly increased in the UTI positive
group, whereas serine and asparagine were decreased (Figure 2.7).
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Figure 2.6 Comparison of the concentration of the precursors of biogenic amines in
Healthy vs UTI positive patients
Control consists of the urine of healthy patients (n=10). TMAO, which is the precursor of
TMA, was significantly decreased. Only the samples positive for UPEC were included in
this analysis (n=15). Black lines indicate the median and the red dashed lines represent the
mean. Significant differences were determined on log-transformed values using a twosample t-test (*p≤0.05).

53

Figure 2.7 Comparison of the concentration of amino acids in Healthy vs UTI positive
patients
Control consists of the urine of healthy patients (n=10). Glutamic acid and aspartic acid are
significantly elevated in UTI patients, while serine and asparagine are significantly lower.
Only the samples positive for UPEC were included in this analysis (n=15). Significant
differences were determined on log-transformed values using a two-sample t-test (*p≤0.05,
**p≤0.005).
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2.4.3

In vitro analysis of UPEC strains in sterile urine

To better understand the metabolic dynamics involved in the production of biogenic
amines by UPEC, the presence of metabolites from four different clinical UPEC strains
grown in sterile female urine was assessed over 24 hours. Many of the biogenic amines
identified in clinical samples were also found in vitro and showed significant changes
within 3 hours (Figure 2.8 and 2.9).
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Figure 2.8 Time course analysis on the formation and uptake of biogenic amines and
their precursors by different UPEC strains
Precursors on the left column and biogenic amines on the right. TMAO was analyzed semiquantitatively based on the log of its peak area. Metabolite levels standardized using the
control as a baseline, which consisted of sterile urine spiked with LB media. A linear mixedeffect model with repeated measures was used to calculate statistical significance. Tukey test
was used to determine individual differences and to control for type I error (Tables 2.2 and
2.3). The horizontal significance line and p-value correspond to the main effect of Time over
the concentration of each metabolite after 24h. Vertical significance corresponds to the
comparison of each strain vs the control. Data are presented as means of 3 independent
experiments ± SEM. (*p≤0.05, ****p≤0.0001).

56

Figure 2.9 Time-course analysis of the formation and uptake of amino acids by different
UPEC strains
Metabolite levels standardized using the control as a baseline, which consisted of sterile
urine spiked with LB media. A linear mixed-effect model with repeated measures was used
to calculate statistical significance. Tukey post-hoc test was used to determine individual
differences and to control for type I error (Tables 2.2 and 2.3). The horizontal significance
line and p-value correspond to the main effect of Time over the concentration of each
metabolite. Vertical significance corresponds to the comparison of each strain vs the control
after 24h. Data are presented as means of 3 independent experiments ± SEM. (**p≤0.01,
****p≤0.0001).

Similar trends in terms of metabolite changes were observed between all five tested
UPEC strains (Tables 2.2 and 2.3), showing an accumulation of cadaverine and TMA,
whereas a maximal amount of putrescine was produced after 3h and diminished
thereafter. Except for cystine, where an accumulation over time was observed, most
amino acids were reduced in concentration by the UPEC strains during the incubation.
Alanine showed significant spikes at hours 3 and 6 by strains IA2 and 536 respectively
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and was degraded thereafter; after 24h only strain J96 was significantly different from the
control. Histidine and tyramine did not show a major change in amounts relative to their
starting concentrations. The amino acids: aspartic acid, methionine, isoleucine, valine,
leucine, glutamine, glycine, and threonine were not included in this analysis as they were
below the detection limit of the method.
Table 2.2 Multiple comparisons between strains of the concentration of biogenic amines
across time
Only significant values are shown, *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001).

Strain
1

Time
Metabolite

Putrescine

(h)

Strain 2

p value

6

IA2

≤0.0001 ****

12

IA2

0.039

*

IA2

0.0449

*

24

J96

0.0449

*

3

GR-12

≤0.0001 ****

GR-12

≤0.0001 ****

IA2

≤0.0001 ****

J96

≤0.0001 ****

GR-12

≤0.0001 ****

IA2

≤0.0001 ****

J96

≤0.0001 ****

6

536

Significance

Cadaverine 9

level
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GR-12

≤0.0001 ****

IA2

≤0.0001 ****

J96

≤0.0001 ****

GR-12

≤0.0001 ****

IA2

≤0.0001 ****

J96

≤0.0001 ****

GR-12

≤0.0001 ****

3

IA2

≤0.0001 ****

6

IA2

≤0.0001 ****

IA2

0.0131

*

24

J96

0.0131

*

9

IA2

0.0432

*

12

IA2

0.0013

**

IA2

0.0001

****

Cadaverine 24

J96

0.0113

*

GR-12

TMA

3

J96

0.0293

*

IA2

TMA

3

IA2

0.0109

**

12

24

TMA

Putrescine

59
Table 2.3 Multiple comparisons between strains of the concentration of amino acids
and/or biogenic amines precursors across time
Only significant values are shown, *p≤0.05, **p≤0.01, ***p ≤0.001, ****p≤0.0001

Time
Strain 1

Significance

Metabolite

(h)

Strain 2

p value

level

TMAO

3

IA2

≤0.0001

****

GR-12

0.0058

**

J96

≤0.0001

****

GR-12

0.0166

*

Ornithine

6

Arginine

3

IA2

0.002

**

Proline

6

J96

0.0014

**

3

IA2

0.0355

*

6

J96

0.0282

*

3

IA2

0.0331

*

GR-12

0.0013

**

IA2

0.0006

***

J96

0.0001

****

IA2

0.0014

**

9

J96

0.0007

***

12

GR-12

0.0013

**

Alanine

6

Glutamic
536

acid
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Histidine

3

GR-12

0.0303

*

Cystine

6

IA2

0.0002

***

TMAO

3

IA2

0.0187

*

Tryptophan 3

IA2

≤0.0001

****

3

IA2

0.0283

*

IA2

0.0031

**

12

J96

0.0406

*

3

J96

0.0385

*

6

J96

0.0003

***

Tryptophan 3

IA2

≤0.0001

****

Proline

6

J96

0.001

***

Cystine

6

IA2

0.0115

*

536

≤0.0001

****

GR-12

≤0.0001

****

J96

≤0.0001

****

536

≤0.0001

****

GR-12

≤0.0001

****

IA2

≤0.0001

****

536

0.0242

*

GR-12

0.0177

*

Glutamic
GR-12

acid

Ornithine

IA2

3

6

J96

Asparagine

9

61

12

24

2.5

IA2

0.016

*

536

0.005

**

GR-12

0.0163

*

IA2

0.0074

**

536

0.0004

***

GR-12

0.0006

***

IA2

0.0004

***

Discussion

Here, we present a comprehensive profile of the production of odorous compounds
during UPEC-UTI. Only the biogenic amines TMA and putrescine were present at high
concentrations in patients with UTIs compared to controls. This contrasts with results in
patients with BV, where cadaverine and tyramine are the most elevated malodorous
compounds (McMillan et al., 2015; Nelson et al., 2015).
Using an in vitro model, cadaverine was found to be significantly increased, perhaps due
to nitrosative stress (Carlsson et al., 2001; Keay et al., 2014) which is higher in a steadystate culture than in the human bladder, allowing for its accumulation. The in vitro model
provides a static system that allows for better appreciation of the rates of consumption
and production of specific metabolites, while in vivo, there is a continuous flow of urine
into the bladder from the kidneys that replenishes substrates and makes it difficult to
identify the changes in metabolite concentration.
Notably, differences were also found in cadaverine levels between strains. Following
reports that cadaverine production can interfere with the invasive process of UPEC, we
hypothesize that its production is reduced during colonization of the bladder as a means
to enhance infectivity (Maurelli et al., 1998). Thus, the environment of the bladder may
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influence the expression of the genes that regulate cadaverine production and perhaps
explain why previous reports have found contrasting results.
Putrescine levels were increased in vivo and in vitro in agreement with findings in
patients with an overactive bladder (Keay et al., 2014). This is associated with an
increase in ornithine decarboxylase, which has been shown to block the calcium
potassium channel. Since putrescine levels can modulate intracellular calcium levels in
urothelial cells, it suggests a correlation between UTIs and overactive bladder (Tang &
Hazen, 2014) and a role for putrescine in urinary urgency. This was further supported by
the finding that ornithine, a major precursor of putrescine, showed a marked decrease in
the in vitro samples. More studies are warranted to investigate this result.
TMA was one of the metabolites that exhibited a highly significant increase in the present
study. The precursor of TMA, TMAO, was significantly different between the clinical
samples. It is worth investigating whether the increase of TMA during a UTI could affect
other symptoms and signs. Acetylcholine present in urine can be converted into choline
via the enzyme AChE, allowing TMA to be produced from choline through choline TMA
lyase activity. The cholinergic system has an important role in voiding the bladder (Tang
& Hazen, 2014), with acetylcholine from parasympathetic nerves and non-neuronal cells
within the urothelium, affecting, directly and indirectly, muscle contraction (Tang &
Hazen, 2014).
Except for cystine, most of the amino acids analyzed in our time-course were degraded
over time. Previous reports have shown that when UPEC strains are grown in urine,
several genes responsible for amino acid catabolism are upregulated (Snyder et al., 2004).
It is thought that this is an important ability of UPEC to colonize the bladder (Alteri &
Mobley, 2015). Notably, serine was significantly reduced both in vivo and in vitro,
suggesting it is being used as a substrate by UPEC. This is consistent with previous
reports showing upregulation of genes responsible for amino acid catabolism, specifically
D-serine deaminase (dsdA) when UPEC were grown in human urine (Mann et al., 2017;
Snyder et al., 2004). Both D- and L-serine are gluconeogenic amino acids that can be
degraded to produce oxaloacetate or pyruvate, which can enter the TCA cycle, therefore,
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they can be used as a carbon source (Alteri & Mobley, 2015). Furthermore, the
catabolism of D-serine in the urinary tract has been identified as a key signaling
mechanism for virulence gene expression (Anfora et al., 2007; Haugen et al., 2007;
Roesch et al., 2003).
A significant decrease in asparagine levels was also found. Asparagine metabolism by E.
coli has not been extensively studied, but it is thought that the organism can utilize this
amino acid by conversion to aspartic acid using an asparaginase enzyme (Willis &
Woolfolk, 1975). This is in agreement with our results, where asparagine was
significantly reduced while aspartic acid increased.
Overall, this study revealed that the odorous compounds TMA and putrescine are present
at high concentrations during a UTI and are produced by UPEC strains. It is important to
note that these findings do not necessarily mean that higher concentrations of biogenic
amines cause an increase in malodour, and further sensory studies with trained analytical
panelists are required. Nonetheless, our findings open the door to the development of new
ways to reduce urinary malodour, a problem that is particularly prevalent in urinary
incontinence patients and takes days to resolve when antibiotics are administered.

2.6

References

Alteri, C., & Mobley, H. (2015). Metabolism and fitness of urinary tract pathogens.
Microbiology Spectrum, 3, 1–20.
Anfora, A. T., Haugen, B. J., Roesch, P., Redford, P., & Welch, R. A. (2007). Roles of
serine accumulation and catabolism in the colonization of the murine urinary tract
by Escherichia coli CFT073. Infection and Immunity, 75, 5298–5304.
Armstrong, L. E., Maresh, C. M., Castellani, J. W., Bergeron, M. F., Kenefick, R. W.,
LaGasse, K. E., & Riebe, D. (1994). Urinary indices of hydration status.
International Journal of Sport Nutrition, 4, 265–279.
Benton, H. P., Want, E. J., & Ebbels, T. M. D. (2010). Correction of mass calibration
gaps in liquid chromatography–mass spectrometry metabolomics data.

64
Bioinformatics, 26, 2488–2489.
Bower, J., Gordon-Raagas, H., & Mulvey, M. (2009). Conditioning of uropathogenic
Escherichia coli for enhanced colonization of host. Infection and Immunity, 77,
2104–2112.
Bower, J., & Mulvey, M. (2006). Polyamine-mediated resistance of uropathogenic
Escherichia coli to nitrosative stress. Journal of Bacteriology, 188, 928–933.
Campilongo, R., Di Martino, M. L., Marcocci, L., Pietrangeli, P., Leuzzi, A., Grossi, M.,
Casalino, M., Nicoletti, M., Micheli, G., Colonna, B., & Prosseda, G. (2014).
Molecular and functional profiling of the polyamine content in enteroinvasive E.
coli : Looking into the gap between commensal E. coli and harmful Shigella. PLoS
One, 9, e106589.
Carlsson, S., Wiklund, N., Engstrand, L., Weitzberg, E., & Lundberg, J. (2001). Effects
of pH, nitrite, and ascorbic acid on nonenzymatic nitric oxide generation and
bacterial growth in urine. Nitric Oxide - Biology and Chemistry, 5, 580–586.
Chambers, M. C., MacLean, B., Burke, R., Amodei, D., Ruderman, D. L., Neumann, S.,
Gatto, L., Fischer, B., Pratt, B., Egertson, J., Hoff, K., Kessner, D., Tasman, N.,
Shulman, N., Frewen, B., Baker, T. A., Brusniak, M. Y., Paulse, C., Creasy, D., …
Mallick, P. (2012). A cross-platform toolkit for mass spectrometry and proteomics.
Nature Biotechnology, 30, 918–920.
Clegg, S. (1982). Cloning of genes determining the production of mannose-resistant
fimbriae in a uropathogenic strain of Escherichia coli belonging to serogroup O6.
Infection and Immunity, 38, 739–744.
Di Guida, R., Engel, J., Allwood, J. W., Weber, R. J. M., Jones, M. R., Sommer, U.,
Viant, M. R., & Dunn, W. B. (2016). Non-targeted UHPLC-MS metabolomic data
processing methods: a comparative investigation of normalisation, missing value
imputation, transformation and scaling. Metabolomics, 12, 93.
Edén, C. S., Freter, R., Hagberg, L., Hull, R., Hull, S., Leffler, H., & Schoolnik, G.

65
(1982). Inhibition of experimental ascending urinary tract infection by an epithelial
cell-surface receptor analogue. Nature, 298, 560–562.
Forsgren-Brusk, U., Yhlen, B., Blomqvist, M., & Larsson, P. (2017). Method for
bacterial growth and ammonia production and effect of inhibitory substances in
disposable absorbent hygiene products. Journal of Wound, Ostomy and Continence
Nursing, 44, 78–83.
Foxman, B. (2003). Epidemiology of urinary tract infections: incidence, morbidity, and
economic costs. American Journal of Medicine, 113, 5–13.
Haug, K., Salek, R. M., Conesa, P., Hastings, J., de Matos, P., Rijnbeek, M.,
Mahendraker, T., Williams, M., Neumann, S., Rocca-Serra, P., Maguire, E.,
González-Beltrán, A., Sansone, S.-A., Griffin, J. L., & Steinbeck, C. (2013).
MetaboLights—an open-access general-purpose repository for metabolomics studies
and associated meta-data. Nucleic Acids Research, 41, D781–D786.
Haugen, B. J., Pellett, S., Redford, P., Hamilton, H. L., Roesch, P. L., & Welch, R. A.
(2007). In vivo gene expression analysis identifies genes required for enhanced
colonization of the mouse urinary tract by uropathogenic Escherichia coli strain
CFT073 dsdA. Infection and Immunity, 75, 278–289.
Hull, R. A., Gill, R. E., Hsu, P., Minshew, B. H., & Falkow, S. (1981). Construction and
expression of recombinant plasmids encoding type 1 or D-mannose-resistant pili
from a urinary tract infection Escherichia coli isolate. Infection and Immunity, 33,
933–938.
Igarashi, K., & Kashiwagi, K. (2018). Effects of polyamines on protein synthesis and
growth of Escherichia coli. Journal of Biological Chemistry, 293, 18702–18709.
Keay, S., Birder, L., & Chai, T. (2014). Evidence for bladder urothelial pathophysiology
in functional bladder disorders. BioMed Research International, 2014, 1–15.
Lam, C. W., Law, C. Y., Sze, K. H., & To, K. K. W. (2015). Quantitative metabolomics
of urine for rapid etiological diagnosis of urinary tract infection: Evaluation of a

66
microbial-mammalian co-metabolite as a diagnostic biomarker. Clinica Chimica
Acta, 438, 24–28.
Lam, C. W., Law, C. Y., To, K. K. W., Cheung, S. K. K., Lee, K., Sze, K. H., Leung, K.
F., & Yuen, K. Y. (2014). NMR-based metabolomic urinalysis: a rapid screening
test for urinary tract infection. Clinica Chimica Acta, 436, 217–223.
Leonardos, G., Kendall, D., & Barnard, N. (1969). Odor threshold determinations of 53
odorant chemicals. Journal of the Air Pollution Control Association, 19, 91–95.
Mann, R., Mediati, D., Duggin, I., Harry, E., & Bottomley, A. (2017). Metabolic
adaptations of uropathogenic E. coli in the urinary tract. Frontiers in Cellular and
Infection Microbiology, 7, 2–15.
Maurelli, A., Fernandez, R., Bloch, C., Rode, C., & Fasano, A. (1998). “Black holes” and
bacterial pathogenicity: a large genomic deletion that enhances the virulence of
Shigella spp. and enteroinvasive Escherichia coli. Proceedings of the National
Academy of Sciences, 95, 3943–3948.
McMillan, A., Renaud, J. B., Gloor, G. B., Reid, G., & Sumarah, M. W. (2016). Postacquisition filtering of salt cluster artefacts for LC-MS based human metabolomic
studies. Journal of Cheminformatics, 8, 44.
McMillan, A., Rulisa, S., Sumarah, M., Macklaim, J. M., Renaud, J., Bisanz, J. E., Gloor,
G. B., & Reid, G. (2015). A multi-platform metabolomics approach identifies highly
specific biomarkers of bacterial diversity in the vagina of pregnant and non-pregnant
women. Scientific Reports, 5, 1–14.
Moreno, E., Andreu, A., Pigrau, C., Kuskowski, M. A., Johnson, J. R., & Prats, G.
(2008). Relationship between Escherichia coli strains causing acute cystitis in
women and the fecal E. coli population of the host. Journal of Clinical
Microbiology, 46, 2529–2534.
Müller, D., Hughes, C., & Goebel, W. (1983). Relationship between plasmid and
chromosomal hemolysin determinants of Escherichia coli. Journal of Bacteriology,

67
153, 846–851.
Nelson, T. M., Borgogna, J.-L. C., Brotman, R. M., Ravel, J., Walk, S. T., & Yeoman, C.
J. (2015). Vaginal biogenic amines: biomarkers of bacterial vaginosis or precursors
to vaginal dysbiosis? Frontiers in Physiology, 6, 1–15.
Norberg, A., Sandström, S., Norberg, B., Eriksson, S., & Sandman, P. (1984). The urine
smell around patients with urinary incontinence. Gerontology, 30, 261–266.
Prince, J. T., & Marcotte, E. M. (2006). Chromatographic alignment of ESI-LC-MS
proteomics data sets by ordered bijective interpolated warping. Analytical
Chemistry, 78, 6140–6152.
Roesch, P. L., Redford, P., Batchelet, S., Moritz, R. L., Pellett, S., Haugen, B. J.,
Blattner, F. R., & Welch, R. A. (2003). Uropathogenic Escherichia coli use D-serine
deaminase to modulate infection of the murine urinary tract. Molecular
Microbiology, 49, 55–67.
Rolker, H., Maldonado, A., Soto-Méndes, M., Melse-Boonstra, A., & Solomons, N.
(2017). Comparative evaluation of the performance of urinary biomarkers of
hydration status among lactating women in the Western Highlands of Guatemala.
The FASEB Journal, 31, 650.2.
Salvatore, S., Salvatore, S., Cattoni, E., Siesto, G., Serati, M., Sorice, P., & Torella, M.
(2011). Urinary tract infections in women. European Journal of Obstetrics
Gynecology and Reproductive Biology, 156, 131–136.
Satink, H., Hessels, J., Kingma, A., van den Berg, G., Muskiet, F., & Halie, M. (1989).
Microbial influences on urinary polyamine excretion. Clinica Chimica Acta, 179,
305–314.
Sj, M., Paur R, & Lindseth G. (2004). Urinary tract infections. Does the smell really tell?
Journal of Gerontological Nursing, 30, 4–9.
Smith, C. A., Maille, G. O., Want, E. J., Qin, C., Trauger, S. A., Brandon, T. R.,

68
Custodio, D. E., Abagyan, R., & Siuzdak, G. (2005). METLIN: a metabolite mass
spectral database. Therapeutic Drug Monitoring, 27, 747–751.
Smith, C. A., Want, E. J., O’Maille, G., Abagyan, R., & Siuzdak, G. (2006). XCMS:
processing mass spectrometry data for metabolite profiling using nonlinear peak
alignment, matching, and identification. Analytical Chemistry, 78, 779–787.
Snyder, J., Haugen, B., Buckles, E., Lockatell, C., Johnson, D., Donnenberg, M., Welch,
R., & Mobley, H. (2004). Transcriptome of uropathogenic Escherichia coli during
urinary tract infection. Infection and Immunity, 72, 6373–6381.
Spagou, K., Wilson, I. D., Masson, P., Theodoridis, G., Raikos, N., Coen, M., Holmes,
E., Lindon, J. C., Plumb, R. S., Nicholson, J. K., & Want, E. J. (2011). HILICUPLC-MS for exploratory urinary metabolic profiling in toxicological studies.
Analytical Chemistry, 83, 382–390.
Tabor, C. W., & Tabor, H. (1985). Polyamines in microorganisms. Microbiological
Reviews, 49, 81–99.
Tandogdu, Z., & Wagenlehner, F. M. E. (2016). Global epidemiology of urinary tract
infections. Current Opinion in Infectious Diseases, 29, 73–79.
Tang, W., & Hazen, S. (2014). The contributory role of gut microbiota in cardiovascular
disease. Journal of Clinical Investigation, 124, 4204–4211.
Tautenhahn, R., Böttcher, C., & Neumann, S. (2008). Highly sensitive feature detection
for high resolution LC/MS. BMC Bioinformatics, 9, 504.
The Good Scents Company. (n.d.-a). TGSC Information System. Trimethylamine.
http://www.thegoodscentscompany.com/data/rw1009301.html
The Good Scents Company. (n.d.-b). TGSC Information System. Cadaverine.
http://www.thegoodscentscompany.com/data/rw1149431.html
The Good Scents Company. (n.d.-c). TGSC Information System. 1,4-Diaminobutane.

69
http://www.thegoodscentscompany.com/data/rw1148651.html#toeuus
The Good Scents Company. (2006). TGSC Information System. Tyramine.
http://www.thegoodscentscompany.com/data/rw1051461.html
Tofalo, R., Cocchi, S., & Suzzi, G. (2019). Polyamines and gut microbiota. Frontiers in
Nutrition, 6, 1–5.
Wang, L., Thomas, B., Warner, K., Wolf, W., & Kwolek, W. (1975). Apparent odor
thresholds of polyamines in water and 2% soybean flour dispersions. Journal of
Food Science, 40, 274–276.
Watson, N., Dunyak, D. S., Rosey, E. L., Slonczewski, J. L., & Olson, E. R. (1992).
Identification of elements involved in transcriptional regulation of the Escherichia
coli cad operon by external pH. Journal of Bacteriology, 174(2), 530–540.
Wheeler, M. A., Smith, S. D., García-Cardeña, G., Nathan, C. F., Weiss, R. M., & Sessa,
W. C. (1997). Bacterial infection induces nitric oxide synthase in human
neutrophils. Journal of Clinical Investigation, 99, 110–116.
Whiteside, S. A. (2018). Contribution of Enterococcus faecalis to urinary tract infection
[Doctoral dissertation]. The University of Western Ontario.
Wickham, H. (2009). ggplot2: Elegant graphics for data analysis. Springer New York.
Willis, R. C., & Woolfolk, C. A. (1975). L-asparagine uptake in Escherichia coli. Journal
of Bacteriology, 123, 937–945.

70

Chapter 3

3

Interstrain variability of human vaginal Lactobacillus
crispatus for metabolism of biogenic amines and
antimicrobial activity against urogenital pathogens

This chapter is reproduced with permission (Appendix B): Puebla-Barragan, S., Watson,
E., van der Veer, C., Chmiel, J., Carr, C., Burton, J., Sumarah, M., Remco, K. & Reid, G.
(2021). Interstrain variability of human vaginal Lactobacillus crispatus for metabolism
of biogenic amines and antimicrobial activity against urogenital pathogens. Molecules,
26, 4538.

3.1 Abstract
Lactobacillus crispatus is the dominant species in the vagina of many women. With the
potential for strains of this species to be used as a probiotic to help prevent and treat
dysbiosis, we investigated isolates from vaginal swabs with Lactobacillus-dominated and
a dysbiotic microbiota. A comparative genome analysis led to the identification of
metabolic pathways for synthesis and degradation of three major biogenic amines in most
strains. However, targeted metabolomic analysis of the production and degradation of
biogenic amines showed that certain strains have either the ability to produce or to
degrade these compounds. Notably, six strains produced cadaverine, one produced
putrescine, and two produced tyramine. These biogenic amines are known to raise
vaginal pH, cause malodour, and make the environment more favourable to vaginal
pathogens. In vitro experiments confirmed that strains isolated from women with a
dysbiotic vaginal microbiota have higher antimicrobial effects against the common
urogenital pathogens Escherichia coli and Enterococcus faecium. The results indicate
that not all L. crispatus vaginal strains appear suitable for probiotic application and the
basis for selection should not be only the overall composition of the vaginal microbiota of
the host from which they came, but also specific biochemical and genetic traits.
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3.2 Introduction
As the dominant organism in the vagina of many healthy women, Lactobacillus
crispatus is thought to be an important contributor to reproductive health (Petrova
et al., 2015). For this reason, the species has been postulated to be an excellent
candidate for probiotic use to restore and maintain vaginal health (Barrons &
Tassone, 2008). Given the high incidence of conditions that result from vaginal
dysbiosis (McMillan et al., 2015; Reid, 2018; Schlabritz-Loutsevitch et al., 2016),
including urinary tract infections (UTIs) and bacterial vaginosis (BV), as well as an
increased risk of sexually-transmitted diseases and preterm labour (Reid, 2018),
vaginal administration of Lactobacillus crispatus has been shown to be an effective
approach to improving women’s health (Cohen et al., 2020). The species’ ability to
adhere to vaginal epithelial cells, block the adherence of pathogenic bacteria, are
believed to be important mechanistic contributors (Andreu et al., 1995), as well as
a broad-spectrum inhibitory activity against a range of Gram-positive and Gramnegative bacteria (Kim & Rajagopal, 2001). This is in part due to the production of
lactic acid, but also other molecules, including peptide-based antimicrobial
bacteriocins may be involved.
Another relevant marker of female urogenital health is the presence or absence of
large amounts of biogenic amines such as putrescine, cadaverine, and tyramine
(Nelson et al., 2015). These compounds, commonly produced by urogenital
pathogens, are elevated in patients with BV (McMillan et al., 2015) and UTI
(Puebla-Barragan et al., 2020), and are known causes of malodour. Beyond that,
large amounts of these compounds increase the odds of vaginal dysbiosis
(Borgogna et al., 2021). Therefore, a high abundance of strains that reduce the
amounts of biogenic amines are desirable in the vaginal environment. Since L.
crispatus is highly abundant in healthy vaginas it is likely that this species has the
ability to regulate the levels of biogenic amines, however, this property has not
been evaluated yet.
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However, it is not clear if these properties and the prevalence of this L. crispatus
species are sufficient to select candidate probiotic strains. As bacterial metabolites
play a role in host health and disease, the present study was designed to examine
the by-products of strains of L. crispatus isolated from healthy women and those
with dysbiosis (van der Veer et al., 2019). Liquid chromatography-mass
spectrometry (LC-MS) was used, given its ability to differentiate by-products of
vaginal microbiota strains (McMillan et al., 2015).

3.3
3.3.1

Materials and methods
Bacterial strains used in this study

The strains, listed in Table S1 (Appendix D), were collected as outlined by van der
Veer et al. (2019) with all material approved by each subject with written consent
and prior approval obtained from the Institutional Review Board (IRB) (document
reference number W12_086 # 12.17.0104).
In brief, swabs were obtained from the Sexually Transmitted Infections clinic in
Amsterdam, the Netherlands. Subjects RL01, RL03, RL04, RL05, RL06, RL08,
RL09, RL10, RL11, RL12, RL16, RL21, RL22, RL26, RL27, and RL32 were
healthy women whose vaginal swabs were dominated by lactobacilli (LVM) as
determined by a Nugent score 0-3; the other subjects had a dysbiotic vaginal
microbiota (DVM) with Nugent score 7-10. The swabs were plated on modified
Trypticase Soy Agar and incubated anaerobically at 37°C for 24h. Following this,
single colonies underwent 16S sequencing for identification purposes. The strains
were then cryopreserved at -80°C in vaginally defined medium plus peptone
(VDMP) (Geshnizgani & Onderdonk, 1992). A total of 28 strains were genome
sequenced using Illumina MiSeq to generate FASTQ workflow. The genomes were
assembled, reordered, and annotated and deposited at DDBJ/ENA/GenBank
(Appendix D).
The 28 strains along with an additional four strains (RL01, RL04, RL12, RL22)
were brought to Canada for antimicrobial analysis but unfortunately 13 did not
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survive (Table S2 in Appendix D). One strain, RL33, then did not grow sufficiently
well for metabolomic analysis.
For antimicrobial testing, Enterococcus faecalis ATCC 19433 (Nilsen et al., 2003),
an oral isolate of Lactobacillus helveticus (Fremaux & Klaenhammer, 1994), and a
beer isolate of Pediococcus pentosaceus (Jiang et al., 2021), were used as positive
controls for the production of bacteriocins as known producers. Strains from
uropathogenic species: Enterococcus faecium ATCC 19434 (Agudelo Higuita &
Huycke, 2014), Escherichia coli UTI 89 (Mysorekar & Hultgren, 2006),
Enterococcus faecalis ATCC 19433 (Agudelo Higuita & Huycke, 2014),
Gardnerella vaginalis ATCC 14018 (Anukam & Reid, 2008), Prevotella bivia
ATCC 29303 (Atassi et al., 2006), and Candida albicans TIMM 1768 (Panthee et
al., 2018), were used as indicator strains.

3.3.2

Phylogenetic and functional genomics analyses

To determine if there was a correlation between the health status of the source of the
strains and their genomic profiles, available L. crispatus genomic assemblies from
BioProject PRJNA390079 were downloaded (NCBI; April 2021). All genomes were
assessed for quality using QUAST v5.0.2 (Gurevich et al., 2013) and completeness using
CheckM 1.1.3 (Parks et al., 2015). Genomic assemblies with N50 <10 kb and
completeness of less than 95% were excluded from further analysis. All 28 genomic
assemblies passed the quality control and were annotated using Prokka v1.14.5
(Seemann, 2014). The --gram pos and --mincontiglen 200 (bp) were specified. The
pangenome was determined using Roary v3.13.0 with the assumptions that a core gene is
defined as gene found in all but one of the isolates (>95%) and a minimum percentage
identify for blastp of 99% (Page et al., 2015). The core gene phylogenetic tree was
constructed using the core gene alignment from Roary in RAxML v8.2.12 (Stamatakis,
2014) with the flags, -f a, -# autoMRE, and -m GTRGAMMA, and visualized using the R
package ggtree v2.4.1 (Yu et al., 2017). Functional capacity of the genomes was analyzed
using eggNOG v5.0 and eggNOG-mapper v2 using the Lactobacillaceae database
(Huerta-Cepas et al., 2017, 2019). Distance matrices for functional category abundance
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was calculated using the R package vegan v2.5-7 (Oksanen et al., 2020) following an
established method (Petrova et al., 2018; Wuyts et al., 2017), and plotted using the R
package ggplot2 v3.3.3 (Wickham, 2016).

3.3.3

LC-MS protocol

Three individual colonies were selected from each strain as independent biological
replicates. Next, they were grown anaerobically for 24 hours in VDMP media at
37°C. Following the addition of methanol in a 1:1 ratio, supernatants were
collected after centrifugation for 10 minutes at 10,000 × g, filtered using 0.45µm
PTFE syringe filters and deposited into HPLC vials. The samples were separated
with an Agilent HILIC-Z column (2.1 × 100 mm, 2.7 µM; Agilent) in an Agilent
1290 HPLC system coupled to a Q-Exactive Quadrupole Orbitrap MS. Mobile
phases consisted of 20 mM ammonium formate in water (A) and 20 mM
ammonium formate in 90% acetonitrile (B). Gradient conditions were as follows:
0 min, 100% B; 0.5 min, 100% B; 5.3 min, 80% B; 9.5 min, 30% B; 13.5 min, 30%
B, 14.5 min 100% B and 16.5 min, 100% B. Heated electrospray ionization (HESI)
was operated in positive mode at a capillary voltage of 3.4 kV. capillary
temperature, 250 °C; sheath gas, 30.00 units; auxiliary gas, 8.00 units; probe heater
temperature, 450 °C; S-Lens RF level, 60.00. Full MS scans were obtained in the
mass range of m/z 58–870 at 35,000 resolution, MS/MS scans set at 17,500
resolution, isolation window of m/z 1.2, and collision energy of 28.

3.3.4

Metabolite identification

The raw files were converted into .MZML format using ProteoWizard (Chambers
et al., 2012) and chromatogram alignment and deconvolution was completed using
the XCMS package in R (Smith et al., 2006). Features were detected with the
centWave method (Tautenhahn et al., 2008) at a 1 ppm tolerance and the prefilter
was set to 3 to 5,000, noise to 1000, and a signal-to-noise threshold of 5. The
obiwarp (Prince & Marcotte, 2006) method was used to correct retention times.
Features present in at least 25% of the samples were grouped. Two-thirds of the
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minimum value of each feature was used to replace zeros. The McMillan
correction was utilized to remove large mass salt clusters and ionization artifacts (
McMillan et al., 2016). Principal component analysis was completed using the
FactoMineR package in R (Lê et al., 2008) and the data was exported and
analyzed. Score plots were generated using the R package ggplot2 v3.3.3
(Wickham, 2016). Biogenic amines were identified by exact mass and
fragmentation patterns.

3.3.5

Biogenic amines pathway analysis

Amino acid sequences relevant to the biosynthetic and biocatalytic pathways of
putrescine, cadaverine, and tyramine were downloaded (NCBI; May 2021). FASTA files
containing the available L. crispatus coding sequences were analysed using blastp. A
graphical summary indicating presence or absence of specific enzymes was elaborated
using the R package ggplot2 v3.3.3 (Wickham, 2016). Pathways’ diagrams were plotted
based on the information available at the Kyoto Encyclopedia of Genes and Genomes
(KEGG) Pathway Database (Kanehisa, 2000, Kanehisa, 2019, Kanehisa et al., 2021).

3.3.6

Agar well diffusion assays

A series of agar well diffusion assays, a standard method used to detect
bacteriocins and other antimicrobial compounds, were performed to identify the
inhibitory profile of the strains (Holder & Boyce, 1994; Tahara et al., 1996). L.
crispatus strains were grown as a lawn across the surface for 48 hours on Columbia
blood agar (CBA) plates anaerobically in a BD GasPak™ EZ container systems at
37°C. To obtain extracellular anti-microbial molecules in a crude fraction, plates
were then frozen at -80°C for 1 hour and thawed at room temperature for 1 hour
while inverted to allow the liquid portion to be released from the agar matrix.
Following thawing the resulting supernatant was collected from the lid of the plate,
the volumes were normalized, the samples were neutralized using NaOH or HCl,
and then all samples were filter sterilized (0.22 µm). To establish the inhibitory
profile, indicator strains were plated on M17 agar (10% lactose). Next, wells of 1
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cm in diameter were bored into the agar using the base of a 1000 µL pipette tip and
50 µL of each individual supernatant sample was deposited into the wells.
Following an incubation period of 48 hours at 37°C the plates were imaged with a
scale and the zones of inhibition were measured using ImageJ software (Schneider
et al., 2012).
Included in all assays were pH neutralized E. faecalis ATCC 19433, L. helveticus,
and P. pentosaceus, L. crispatus supernatants, and a CBA supernatant brought to
pH 5 using lactic acid as positive controls for bacteriocin production and a CBA
supernatant sample that was neutralized, unaltered, and one that was brought to pH
5 with lactic acid and then neutralized as negative controls. The assays were
repeated using indicator strains E. faecium ATCC 19434, E. coli UTI 89, E.
faecalis ATCC 19433, G. vaginalis ATCC 14018, P. bivia ATCC 29303, and C.
albicans TIMM 1768 (N = 4 biological replicates).
To verify the presence of an inhibitory protein within the supernatants, an agar well
diffusion assay with E. faecium ATCC 19434 as an indicator strain was repeated in
two parts with a small subset of strains, one with supernatants that were heated to
85°C for 45 minutes prior to filter sterilization and a second where the supernatants
were treated as described above. The remaining supernatants from this experiment
were also subjected to a protein-degrading trypsin, a protease, using 1 mg/mL final
concentration and an agar well diffusion assay was conducted.

3.3.7

Statistical analysis

Statistical analyses were completed using RStudio version 1.2.1335. Differences in
inhibition areas between groups were evaluated using a linear mixed effects model
to control for individual strain effects; the following R packages were used: rstatix
v0.7.0 (Kassambara, 2021), emmeans v1.6.0 (Lenth, 2021), and FSA v0.8.32 (Ogle
et al., 2021). For differences of the amount of biogenic amines between healthstatus groups a T-test was performed using the R package ggsignif v0.6.1
(Ahlmann-Eltze, 2021). Differences in biogenic amine amounts between strains
were calculated using a one-way analysis of variance (ANOVA) with the Dunnett’s
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test, to correct heteroscedasticity marginal means were used and the matrix of covariance was adjusted, this was performed using the R packages rstatix v0.7.0
(Kassambara, 2021), emmeans v1.6.0 (Lenth, 2021), and sandwich v3.0-1 (Zeileis,
2004).

3.4
3.4.1

Results
Untargeted metabolomics and functional genomics

PCA analysis of the metabolites identified through LC-MS did not find any clustering
between the L. crispatus strains as shown in Figure 3.1. Similarly, neither the
phylogenetic nor the functional analyses revealed any specific grouping according
microbiota status (Figure 3.1 and S1 (Appendix D)).
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Figure 3.1 Phylogenetic and metabolomic clustering analyses
(A) Core gene phylogenetic tree. (B) Untargeted metabolomics. Ellipses represent the
95% confidence intervals. Colour coding represents grouping. Burgundy represents
strains isolated from dysbiotic vaginal microbiota (DVM) and blue represents strains
isolated from Lactobacillus dominated vaginal microbiota (LVM).

3.4.2

Targeted metabolomics

Between isolated strains from Lactobacillus-dominated and dysbiotic vaginal microbiota
groups, no significant differences were identified in the amounts of putrescine,
cadaverine, and tyramine (Figure 3.2). Semi-quantitative analysis was based on the areas
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under the curve of the features corresponding to the amines already present in the media,
or those produced after incubation.

Figure 3.2 Production and degradation of biogenic amines
Semi-quantitative metabolomics analysis of the differences in putrescine (A, D),
cadaverine (B, E), and tyramine (C, D), between the control (VDMP media only) and spent
media by microbiota status (A-C) and by strain (D-E). Burgundy represents strains isolated
from dysbiotic vaginal microbiota (DVM) and blue represents strains isolated from
Lactobacillus dominated vaginal microbiota (LVM). Data are represented as means of
three independent experiments per strain tested (*p≤0.05, **p≤0.01, ***p≤0.001,
****p≤0.0001).
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3.4.3

Biogenic amines’ pathway analysis

The analysis of the biosynthetic and biocatalytic pathways for putrescine, tyramine, and
cadaverine (Figure 3.3 and Figure 3.4) revealed that all strains possess the gene that
encodes for the enzyme lysine racemase, which catalyzes the bidirectional reaction from
L-lysine to D-lysine. The gene encoding for lysine decarboxylase was absent from all
strains; this enzyme is responsible for the decarboxylation of L-lysine. However, all
strains appear to have the gene that encodes for the enzyme D-ornithine/D-lysine which
decarboxylates D-lysine into cadaverine and D-ornithine into putrescine. Only six strains
have the encoding sequence for agmatine deiminase (RL03, RL14, RL16, RL20, RL31,
RL32), however none have the gene encoding N-carbamoylputrescine amidase, which is
required in addition to produce putrescine from agmatine. All strains have the genes that
encode for arginine decarboxylase and arginine racemase which convert L- and Darginine into putrescine, respectively. Arginine racemase also catalyzes the two-way
reaction between L- and D- ornithine. All strains also possess the gene for ornithine
decarboxylase which synthesizes putrescine from L-ornithine. Only strain 20 has the gene
encoding for tyrosine decarboxylase, which converts L-tyrosine into tyramine.
Of the degrading enzymes, all strains except RL09, RL15, RL17, RL20, and RL30 have
the gene for the enzyme diamine oxidase, which converts putrescine into 4-aminobutanal.
Strain RL14 also has the gene for putrescine aminotransferase, which also converts
putrescine into 4-aminobutanal. Additionally, all strains have genes encoding
multicopper oxidases. A summary of these of where the genes encoding for these
enzymes are found in known pathways findings can be found in Figure 3.5.
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Figure 3.3 Metabolic pathways for the synthesis and degradation of tyramine (A) and cadaverine (B)
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Figure 3.4 Metabolic pathways for the synthesis and degradation of putrescine
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Figure 3.5 Key enzymes in the metabolism of biogenic amines
Summary of the presence or absence of genes encoding for the enzymes involved in the
biosynthesis (red) or degradation (blue) of biogenic amines. All available genomes were
used for this analysis.
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3.4.4

Antibacterial activity

Agar well diffusion assays were conducted using 19 of the L. crispatus strains, against E.
faecium, E. coli, G. vaginalis, P. bivia, and C. albicans as indicator strains. Results
showed that strains isolated from dysbiotic patients were more effective in inhibiting E.
faecium and E. coli than those isolated from healthy patients (Figure 3.6). No significant
differences were observed in the inhibition of G. vaginalis, C. albicans, and P. bivia.
The supernatants and treatments with heat and trypsin showed no inhibition of E. faecium
(Supplementary Figure S3, Appendix D).
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Figure 3.6 Differences between the antimicrobial capacity of L. crispatus strains isolated
from dysbiotic and Lactobacillus dominated vaginal environments.
Burgundy represents strains isolated from dysbiotic vaginal microbiota (DVM; N = 8)
and blue represents strains isolated from Lactobacillus dominated vaginal microbiota
(LVM; N = 11). A linear mixed effects model to control for individual strain effects was
used to evaluate differences between the groups (*p ≤ 0.05).

3.5

Discussion

Although the L. crispatus species has been proposed as an excellent candidate for
probiotic use to restore and maintain vaginal health because of its preponderance in
healthy women, the present study showed that not every strain necessarily has the
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ideal properties. Untargeted metabolomic analysis of 18 freshly isolated vaginal
strains of Lactobacillus crispatus did not show any distinguishable groupings
fitting healthy versus dysbiotic origins. Similarly, genomic and functional analyses
of all available genomes did not reveal any specific pattern to suggest that the
health status of the source host plays a significant role in the specific characteristics
of the strains. Altogether, the results showed that all the strains are highly similar
both in terms of genes and metabolism.
However, when a more specifically focused targeted metabolomic analysis was
performed of the production and degradation of biogenic amines it showed that
strains have either the ability to produce or to degrade these compounds. In
addition, the evaluation of specific amino acid sequences and metabolic pathways
showed that all strains have the genetic potential to produce and to degrade
cadaverine and putrescine, while only strain RL20 can produce tyrosine
decarboxylase which produces tyramine. Nonetheless, data obtained in vitro
showed that other two strains (i.e. RL16 and RL14) can produce tyramine when
grown in conditions that simulate the vaginal environment (unfortunately strain
RL20 was not available for this analysis). These findings have implications for
products using L. crispatus ostensibly for vaginal health, as potentially some of
these strains may actually produce malodorous compounds. Altogether, these
results also suggest that targeted approaches are better suited for the identification
of probiotic candidates than those that provide a global overview.
In a study of another lactic acid bacterium, E. faecium E17, the tyrosine
decarboxylation pathway was found to be a key survival mechanism in low acid
and nutrient-depleted conditions (Pereira et al., 2009). Within enterococci, the
functioning of this pathway also contributes to the binding and immunomodulation
of enterocytes. Another species, Enterococcus durans IPLA655, uses this ability as
a survival and colonization mechanism that enhances adhesion to the intestinal
epithelium (Gómez et al., 2010). The capacity of L. crispatus to utilize this
pathway could be a method of removing the tyrosine for use by enterococci, similar
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to the iron sequestering abilities of L. crispatus during menstruation (Elli et al.,
2000).
The production of biogenic amines, within the vagina is linked to an increase in pH
which promotes colonization by BV-associated bacteria. Although all strains
showed the genetic potential to produce cadaverine and putrescine, only six strains
(i.e. RL04, RL10, RL12, RL13, RL22, and RL29) produced cadaverine in vitro and
one (i.e. RL04) produced putrescine. This could be a result of an adaptation of
these strains to conditions of higher pH, and under stressful in vitro conditions they
reacted by raising pH. Unfortunately, this makes the environment more favourable
to pathogens, plus these compounds emit malodour. Such characteristics are not
ideal for vaginal probiotics.
One strain showed in vitro capacity to degrade cadaverine (RL05), and three could
reduce the amount of tyramine (RL03, RL09, RL12, RL13, RL14, and RL26).
Based on our analysis of metabolic pathways, degradation of putrescine is most
likely being converted to 4-aminobutanal through diamine oxidase, while tyramine
are most likely to be degraded by a multicopper oxidase (Li et al., 2021; Pištěková
et al., 2020). Interestingly, there are strains, such as RL01 and RL04 that both
produce and degrade biogenic amines. This suggests an adaptation ability of the
species depending on what compounds are in the surroundings. The required
enzymes for degrading activities are present in the genomes, so it might require
certain conditions and larger concentrations of amines in the media to activate
them. This capacity makes them good probiotic candidates. A potential L. crispatus
based probiotic that could degrade malodorous compounds efficiently would be a
welcome addition to the current treatments of conditions such as BV.
Admittedly, only one strain was isolated from each host (van der Veer et al., 2019),
which makes it possible that several L. crispatus strains co-exist in the vaginal
environment creating a symbiotic relationship where some produce biogenic
amines and others can degrade them. More studies are required to better
characterize this relationship. Furthermore, not all strains were tested in vitro
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because they were not viable under the applied lab conditions. Research on the
specific growth requirements for reproducible growth of these strains is on-going.
Antimicrobial activity was significantly higher in the strains isolated from
dysbiotic patients, suggesting adaptation due to be sourced from more competitive
environments. This inhibitory activity ceased following treatment with the protease
trypsin, and heating of the supernatants to 85°C for 45 minutes, indicating that the
observed antimicrobial properties resulted from a heat-labile protein. This suggests
a potential bacteriocin, compounds regarded as being important defence factors for
lactobacilli (Borges et al., 2014). These antimicrobial proteins typically have a very
narrow spectrum, usually only inhibiting closely related species (Zamfir et al.,
1999). However, those produced by Lactobacillus spp. are known to have a much
broader spectrum of activity, including against Gram-negative bacteria (McGroarty
& Reid, 1988). Nonetheless, further studies are required to express and further
characterize the putative antimicrobial peptides that are causing this activity.
Strain L. crispatus CTV-05 is already being developed as an intravaginal probiotic,
but it only appears to be effective if the subject is devoid of indigenous L. crispatus
(Antonio et al., 2009). This might suggest competition for receptor sites or some
other quorum sensing effect that limits foreign strain colonization, but these
mechanisms have not been explored to date and its ability to produce or degrade
biogenic amines has not been reported.
In summary, the findings from the present study suggests that metabolic readouts
along with a strain’s genomic capacity should be part of the characterization of
candidate probiotics. There is a strong need to improve women’s health. The option
of using probiotic L. crispatus strains to this end, is worthy of further study, but
specific, well-documented characteristics must guide the selection.

3.6

Ethics declaration

The research proposal for this study was assessed by the ethics review board of the
Academic Medical Center (AMC), University of Amsterdam, The Netherlands. The
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review board deemed that no additional ethical approval was required for this study, since
the vaginal samples used here were collected as part of routine procedure for cervical
examinations at the STI clinic in Amsterdam (document reference number W12_086 #
12.17.0104).
Clients of the STI clinic were notified that their samples could be used for scientific
research, after anonymization of client clinical data and samples. The data and samples of
clients who refused were discarded. This procedure was approved by the AMC ethics
review board (reference number W15_159 # 15.0193).
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Chapter 4

4

Probiotics to reduce biogenic amines that cause urogenital
malodour

4.1

Introduction

The biogenic amines (BAs) tyramine, cadaverine, putrescine, and tyramine, have been
correlated with malodour in the urogenital tract of women with dysbiosis. Patients with
conditions such as bacterial vaginosis (BV) and urinary tract infection (UTI) suffer from
malodour, negatively impacting their life-quality. Unfortunately, the gold standard
treatment for BV and UTI is a course of antibiotics, but these do not target malodour nor
do they provide relief for at least three days. Thus, a remedy that can augment antibiotics
or target reduction in malodour more quickly would represent a significant advancement.
Probiotics, defined as ‘live microorganisms that, when administered in adequate amounts,
confer a health benefit on the host’ (FAO/WHO Working Group, 2002; Hill et al., 2014),
have been used for decades to manage and prevent dysbiosis of the female urogenital
tract. Lacticaseibacillus rhamnosus GR-1 (LGR-1) and Limosilactobacillus reuteri RC14 have been proven to effectively aid in regulating homeostasis. Indeed, LGR-1 is the
most widely studied probiotic for urogenital health (Petrova et al., 2018, 2021), and its
genome indicates that it can thrive in the vaginal environment. When used in conjunction
with LRC-14 it can decrease recurrence of BV, UTI and effectively inhibit the yeast
Candida albicans, which is one of the most frequent vaginal pathogens (Beerepoot et al.
;Martinez et al., 2009; Reid, 2017; Vujic et al., 2013). Additionally, the combination
taken orally with and after antibiotic treatment aids in the replenishment of indigenous
species such as Lactobacillus crispatus, which are predominant in a healthy urogenital
environment (Macklaim et al., 2015).
As shown on Chapter 3, several strains of L. crispatus have the potential to degrade BAs.
In the present study, five promising candidates were tested against BAs, along with L.
crispatus ATCC 33820, LGR-1, and LRC-14.
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Previous studies suggested that BAs, are not only produced by some pathogens, but they
act as virulence factors that increase the urogenital pH, reduce production of lactic acid,
and lower the abundance of lactobacilli (Borgogna et al., 2021; Nelson et al., 2015). The
relationship between these malodorous compounds and lactobacilli survival was also
examined.
The long-term goal was to establish a basis for a novel approach to manage urogenital
dysbiosis and malodour, thereby, benefiting millions of women around the world.

4.2
4.2.1

Materials and methods
Lactobacillus crispatus clinical strains

The L. crispatus strains used in this study were selected based on previous characteristics
(Chapter 3) and depending on their potential to degrade BAs. Strains were provided by
van der Veer et al (2019) with all material approved by each participant with written
consent and from the Institutional Review Board (IRB). They originated from vaginal
swabs obtained from women attending the Sexually Transmitted Infections clinic in
Amsterdam, The Netherlands. The samples came from two groups of women: one with a
healthy vaginal microbiota (based upon Nugent score 0-3), or those with dysbiosis
(Nugent score 7-10). The swabs were plated on modified Trypticase Soy Agar and
incubated anaerobically at 37°C for 24h. Next, single colonies underwent 16S rRNA
gene sequencing for identification purposes. The strains were then cryopreserved and
stored at -80°C in vaginally defined medium plus peptone (VDMP) (Geshnizgani &
Onderdonk, 1992). Additional strains were obtained from four healthy premenopausal
women in London, Ontario aged between 25 and 30 years old who consented to partake
in the study, approved by the Health Sciences Research Ethics Board at The University of
Western Ontario (Collins et al., 2017) (see Appendix E). The subjects self-swabbed their
lateral vaginal walls using sterile Dacron swabs. Vaginal pH was confirmed to be
approximately 4.5 by using pHem-Alert applicator keys (Gynex Corporation)). Swabs
were Gram stained (Becton, Dickinson & Company) and scored using the Nugent system
(Nugent et al., 1991; Spiegel et al., 1983).
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4.2.2

Biogenic amine production and degradation experiments

A degradation assay using LGR-1, LRC-14, and L. crispatus ATCC 33820 was
performed, along with a polymicrobial culture containing LGR1 and RC-14. Four
individual colonies of each organism were grown in Man-Rogosa-Sharpe (MRS) broth
medium (VWR) at 37°C anaerobically for 24 hours. Next, 10 µL of the initial liquid
cultures were grown for 24 hours anaerobically at 37°C in 10 mL of VDMP
supplemented with 100 ppm of either cadaverine, putrescine, and tyramine or a control of
VDMP only. These were subsequently analyzed using LC-MS/MS.
To test their ability to degrade amines at similar concentrations as those in vaginal
dysbiosis (Wolrath et al., 2001), three individual colonies of five L. crispatus strains (i.e.
RL01, RL03, RL05, RL09, and RL12) as well as the type strain (ATCC 33820) were
grown in MRS medium at 37°C anaerobically for 24 hours. Then, 10 µL were subcultured in 2 mL of either VDMP or amine-VDMP (200 ppm of cadaverine, 200 ppm of
putrescine, and 200 ppm of tyramine) and grown anaerobically at 37°C for 24 hours.
These samples were analysed using HPLC-UV.

4.2.3

Induction assays

To identify whether L. crispatus undergoes adaptation after exposure to BAs, five
individual colonies of L. crispatus ATCC 33820 were grown in 2 mL of amine-VDMP
anaerobically at 37°C for 24 hours, then 10 µL was inoculated into 2 mL of amineVDMP under the same conditions; these were deemed the ‘induced’ group. Meanwhile,
the ‘uninduced’ group was derived from 5 individual colonies of L. crispatus ATCC
33820 grown in 2 mL of VDMP anaerobically at 37°C for 24 hours and subsequently
sub-cultured in amine-VDMP. Next, HPLC-UV analysis was performed.
To assess whether the metabolites produced by L. crispatus had the ability to degrade
BAs, the spent media of the original liquid cultures was filtered sterilized (0.22 µm) and
incubated under the same conditions as the previous samples in amine-VDMP. These
groups were designed ‘induced’ and ‘uninduced’ filtrates.
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The effect of pH on the tolerance to amines of ‘induced’ and ‘uninduced’ cultures was
measured by inoculating a 1:100 dilution of the liquid cultures in 240 µL of BA-media
(amine-VDMP + 50 ppm of TMA). The control consisted on VDMP only (n = 5). The
pH was adjusted using either NaOH or HCl. Absorbance at 600 nm was measured every
30 min during 24 hours in an automatic plate reader. Finally, pH was measured using pH
strips (Eorta). The R package growthcurveR (Sprouffske, 2020) was used to model the
bacterial growth kinetics and to calculate relevant growth parameters (i.e. maximum
growth capacity, area under the curve, time at inflection point, and doubling time).
Data analysis was performed based on lineal models generated per each growth
parameter. Families were defined as either induced or uninduced. Within each family,
multiple comparisons and control for type I error were performed using Tukey’s post-hoc
test (Tables 4.1, 4.3, 4.5, and 4.7). Next, individual contrasts between both families at
every pH were performed (Tables 4.2, 4.4, 4.6, and 4.8).

4.2.4

LC-MS/MS protocol

After incubation, 250 µL of each liquid culture was aliquoted and diluted 1:3 with pure
methanol then vortexed and incubated on ice for 30 minutes, followed by centrifugation
at 16000 × g for 10 minutes. Supernatants were filtered into vials for analysis (0.22 µm
PTFE syringe filters) which was carried out using a Q-Exactive Quadrupole Orbitrap MS,
coupled to an Agilent 1290 HPLC system with an Agilent HILIZ-Z (2.1 × 100 mm, 2.7
µm). The mobile phase A consisted of 20 mM ammonium formate in water, and phase B
was 20 mM ammonium formate in 90% acetonitrile. Analytes were eluted with the
following gradient: 0 min, 100% B; 0.5 min, 100% B; 5.3 min, 80% B; 9.5 min, 30% B;
13.5 min, 30% B; 14.5 min 100% B; and 16.5 min, 100% B. Conditions for heated
electrospray ionization (HESI) were as follows: HESI(+) capillary voltage, capillary
voltage, 3.5 kV ; capillary temperature, 250 °C; sheath gas, 30.00 units; auxiliary gas,
8.00 units; probe heater temperature, 450 °C; S-Lens RF level, 60.00. The instrument was
operated with a top 3 data-dependent acquisition protocol with a full MS scan in the mass
range of m/z 1.2 and collision energy of 28. Authentic standards were used for calibration
curves (cadaverine, putrescine, and tyramine), acquired from Sigma Aldrich (St. Louis,
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MO). Compound identification and quantification was performed using the software
Xcalibur (Thermo Fisher Scientific, Waltham, MA).

4.2.5

HPLC-UV analysis

Due to pandemic-related restrictions, further access to LC-MS was not possible and the
rest of the analyses were carried out in-house using HPLC-UV. Bacterial cultures, and
their supernatants, were also prepared by diluting them 1:10 with water, incubating them
on ice for 30 min and centrifuging at 16000 × g for 10 minutes. Samples were prepared
for derivatization by adding 250 µL of 0.5 KH2PO4 buffer (pH = 11) and 10 µL of 1 M
NaOH. Next, 500 µL of p-toluenesulfonyl chloride (10 mg/ml, Sigma Aldrich, St. Louis,
MO) were added and samples incubated at 56 for 10 min. The reaction was stopped with
the addition of 50 µL of 1M HCl and samples were filtered into vials (0.45 µL PTFE
syringe filters) (Dziarkowska et al., 2008).
Analysis was carried out using a mobile phase in isocratic mode composed of 60%
acetonitrile and 40% HPLC grade water (Thermo Fisher Scientific, Waltham, MA). The
flow rate was 1 mg/mL Authentic standards for putrescine, cadaverine, and putrescine
were used, and α-aminobutyric acid was an internal standard, all acquired from Sigma
Aldrich (St. Louis, MO). Analyte identification and quantification was performed using
the Chemstation software (Agilent, Santa Clara, CA).

4.2.6

Analysis of the impact of biogenic amines on the vaginal
microbiota

To assess the impact that biogenic amines have on the vaginal microbiota, an adaptation
of the in vitro polymicrobial vaginal culturing model described previously was used
(Collins et al., 2017). Briefly, bacteria collected from vaginal swabs were grown
anaerobically for 36 h in different media: VDMP supplemented with either 200 ppm of
cadaverine, 200 ppm of putrescine, 200 ppm of tyramine, or 50 ppm of TMA, BAVDMP, and VDMP.
Microbiota analysis was performed by amplification of the V4 region of 16S ribosomal
DNA, which was be then sequenced using the Illumina MiSeq to detect shifts in
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microbial abundance (Al et al., 2020). Earth Microbiome universal primers, 515F and
806R, were used for PCR amplification. Primers consisted of an Illumina adapter and
four random nucleotides, one of 24 unique 12-mer barcodes, and the corresponding
annealing primer (Parada et al., 2016). A Biomek® 3000 Laboratory Automation
Workstation (Beckman-Coulter, Mississauga, ON) was used for PCR set-up.
Amplification was performed in an Eppendorf thermal cycler (Eppendorf, Mississauga,
ON) with an initial raise in temperature of 95°, then 25 cycles of one minute each at
95°C, 52°C, and 72°C. Purified amplicons were then paired-end sequenced with 250
cycles on an Illumina MiSeq platform (San Diego, CA) (Parada et al., 2016).
Data were exported as raw fastq files. Quality control was performed following the
DADA2 pipeline (Parada et al., 2016). Amplicon sequence variants (SVs) and samples
were selected with more than 1,000 filtered reads, SVs present at 1% relative abundance,
and SVs larger than 10,000 total reads across all samples. Taxonomy was assigned using
the SILVA (c132) training set. (Parada et al., 2016). Downstream analysis was performed
with the ALDEx2 (Fernandes et al., 2013, 2014; Gloor et al., 2016), Vegan (Oksanen et
al., 2020), rstatix (Kassambara, 2021), and emmeans (Lenth, 2021) R packages.

4.2.7

Statistical analyses

All data analyses were performed using RStudio. One-way analysis of variances
(ANOVAs) and all post-hoc tests were done with the R packages rstatix v0.7.0
(Kassambara, 2021). To correct heteroscedasticity marginal means were used and
the matrix of co-variance was adjusted. This was performed using the R packages,
emmeans v1.6.0 (Lenth, 2021) and sandwich v3.0-1 (Zeileis, 2004). Figure 4.1 was
done using the software GraphPad Prism 8. The rest of the figures were made with
the R package ggplot2 (Wickham, 2016).

4.3
4.3.1

Results
Lactobacilli growth in biogenic amines

When grown in VDMP supplemented with 100 ppm of cadaverine, putrescine, or
tyramine as independent experiments, only L. crispatus ATCC 33820 showed statistically
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significant reduction of cadaverine and putrescine. Meanwhile, LGR-1 produced a
significant amount of tyramine when grown by itself. Results are summarized in Figure
4.1.

Figure 4.1 Metabolism of biogenic amines by different lactobacilli strains.
Data are presented as means of 4 independent experiments ± 95% confidence intervals (CI).
One-way ANOVA with the Dunnet correction for multiple comparisons was used to
calculate statistical significance, * p ≤ 0.05).
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Figure 4.2 shows that all the recently isolated L. crispatus strains could significantly
reduce the concentration of putrescine and cadaverine when supplemented at 200 ppm
each, with the exception of strain RL12 which produced cadaverine. Furthermore, all
strains completely removed tyramine from the media (data not shown).

Figure 4.2 Metabolism of biogenic amines by different L. crispatus strains in amineVDMP.
One-way ANOVA with the Dunnet correction for multiple comparisons was used to
calculate statistical significance (*p≤0.05, **p≤0.01, ***≤0.001, p ****p≤0.0001). Data are
presented as means of 3 independent experiments ± 95% CI.
When degradation assays were carried out using cultures of L. crispatus ATCC 33820
that had been originally exposed to putrescine, cadaverine, and tyramine (i.e. ‘induced’
cultures), all preparations from either whole cells or supernatants reduced the amount of
all tested amines below 60%. There was no statistically significant difference between
treatments for reduction ability of cadaverine. In the case of putrescine, ‘induced’
bacterial cultures showed greater degradation than the rest of the treatments. Both the
whole cells and the supernatant of ‘induced’ cultures reduced significantly more
tyramine. Results are presented in Figure 4.3.
Due to the physicochemical properties of TMA, none of the analytical methods (i.e. LCMS/MS and HPLC-UV) were suitable for detecting this compound at relevant
concentrations. Therefore, it was excluded.
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Figure 4.3 Biogenic amines exposure assay.
One-way ANOVA with the Tukey pot-hoc test for multiple comparisons was used to
calculate statistical significance (*p≤0.05, **p≤0.01, ***≤0.001, p ****p≤0.0001). Data are
presented as means of 3 independent experiments ± 95% CI.

4.3.2

Effect of biogenic amines and pH on the growth of Lactobacillus.

Originally the pH of non amine-supplemented VDMP (control) was 6.71 and that of BA
media was 7.04. An additional set of each media was prepared with adjusted pH that
corresponded its counterpart (i.e. control at 7.04 and BA-media at 6.71). At the end of the
incubation period all treatments reached a final pH of 4.5.
Results, plotted in Figure 4.4, showed that both ‘induced’ and ‘uninduced’ cultures had
the most and fastest growth when cultured in BA-VDMP that had been adjusted to a
lower pH. They were followed by ‘induced’ and ‘uninduced’ cultures grown in VDMP at
its original pH (6.71). Next, were the bacteria grown in BA-media at its original pH
(7.04), in which case ‘induced’ cultures showed better growth than their ‘uninduced’
counterparts. The slowest and lowest growth was observed when bacteria were grown in
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VDMP at an adjusted higher pH (7.04). Statistical analyses of different relevant growth
parameters between groups are summarized in Tables 4.1 through 4.8.
Analyses on the impact of exposure to biogenic amines on the vaginal microbiota are
shown on Figure 4.5. Results revealed that Lactobacillus abundance was significantly
reduced when cultures were exposed to 200 ppm of cadaverine or to BA-media.

107

Figure 4.4 Effect of biogenic amines and pH on the growth of L. crispatus
Data are presented as the means of 5 independent experiments. A) Bacterial growth
curves measured by absorbance at a wavelength of 600 nm. B) Logistic areas under the
curve. C) Time at inflection. D) Doubling times.

Table 4.1 Effect of biogenic amine supplemented media on maximum possible
population (K)
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Multiple comparisons between control group (non-supplemented VDMP media, original
pH 6.71) and Biogenic amine (BA) media (original pH). An additional media of each was
prepared and its pH adjusted to mimic its supplemented/non-supplemented counterpart.
Induced samples were grown from cultures previously exposed to BAs and uninduced
from cultures grown in non-supplemented VDMP.
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Table 4.2 Effect of previous amine exposure on maximum possible population (K)
Multiple comparisons between induced samples grown from cultures previously exposed
to BAs and uninduced from cultures grown in non-supplemented VDMP. Cultures grown
in (non-supplemented VDMP media, original pH 6.71) and biogenic amine (BA) media
(original pH). An additional media of each was prepared and its pH adjusted to mimic its
supplemented/non-supplemented counterpart.
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Table 4.3 Effect of biogenic amine supplemented media on time at inflection
Multiple comparisons between control group (non-supplemented VDMP media, original
pH 6.71) and Biogenic amine (BA) media (original pH). An additional media of each was
prepared and its pH adjusted to mimic its supplemented/non-supplemented counterpart.
Induced samples were grown from cultures previously exposed to BAs and uninduced
from cultures grown in non-supplemented VDMP.
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Table 4.4 Effect of previous amine exposure on time at inflection
Multiple comparisons between induced samples grown from cultures previously exposed
to BAs and uninduced from cultures grown in non-supplemented VDMP. Cultures grown
in (non-supplemented VDMP media, original pH 6.71) and biogenic amine (BA) media
(original pH). An additional media of each was prepared and its pH adjusted to mimic its
supplemented/non-supplemented counterpart.
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Table 4.5 Effect of amine supplemented media on doubling time
Multiple comparisons between control group (non-supplemented VDMP media, original
pH 6.71) and Biogenic amine (BA) media (original pH). An additional media of each was
prepared and its pH adjusted to mimic its supplemented/non-supplemented counterpart.
Induced samples were grown from cultures previously exposed to BAs and uninduced
from cultures grown in non-supplemented VDMP.
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Table 4.6 Effect of previous amine exposure on doubling time
Multiple comparisons between induced samples grown from cultures previously exposed
to BAs and uninduced from cultures grown in non-supplemented VDMP. Cultures grown
in (non-supplemented VDMP media, original pH 6.71) and biogenic amine (BA) media
(original pH). An additional media of each was prepared and its pH adjusted to mimic its
supplemented/non-supplemented counterpart.
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Table 4.7 Effect of amine supplemented media on logistic area under the curve
Multiple comparisons between control group (non-supplemented VDMP media, original
pH 6.71) and Biogenic amine (BA) media (original pH). An additional media of each was
prepared and its pH adjusted to mimic its supplemented/non-supplemented counterpart.
Induced samples were grown from cultures previously exposed to BAs and uninduced
from cultures grown in non-supplemented VDMP.
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Table 4.8 Effect of previous amine exposure on logistic area under the curve
Multiple comparisons between induced samples grown from cultures previously exposed
to BAs and uninduced from cultures grown in non-supplemented VDMP. Cultures grown
in (non-supplemented VDMP media, original pH 6.71) and biogenic amine (BA) media
(original pH). An additional media of each was prepared and its pH adjusted to mimic its
supplemented/non-supplemented counterpart.
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Figure 4.5 Impact of biogenic amines on the vaginal microbiota.
A) Bar plot of relative abundances. Each colour represents a genus and top numbers indicate each subject from which the sample
originated. X-axis denotes which treatment each swab underwent.
B) Relative abundances of Lactobacillus spp. in different media (centered log ratios (CLR) are plotted)

117

4.4

Discussion

Probiotic strains LRC-14 and LGR-1 showed some degradation of cadaverine and putrescine
(both individually and as a co-culture). Interestingly, LGR-1 cultured individually produced a
statistically significant amount of tyramine; however, when co-cultured with LRC-14 this effect
was not observed. These two strains are administered in combination, and these findings
suggests a further benefit of this cooperation (Anukam et al., 2006; Karlsson et al., 2012; Rafael
Martinez et al., 2009; Reid et al., 2001, 2003).
Of significant note, L. crispatus ATCC 33820 and five vaginal L. crispatus strains showed
statistically significant reduction of putrescine, cadaverine and tyramine within 24 hours. The
exception was strain RL12 which produced tyramine. Cultures of the type strain which had been
either exposed (‘induced’) or not (‘uninduced’) to biogenic amines prior to the experiment
resulted in reduced concentration of biogenic amines from the media. Furthermore, bacteria
originating from ‘induced’ cultures had a higher capacity to degrade amines, better resistance to
high pH, and they grew better in the presence of amines. Similarly, filtered supernatants from
‘uninduced’ and especially ‘induced’ cultures were able to reduce the concentration of amines.
Interestingly, when the high pH caused by BA was adjusted, L. crispatus grew better than in the
medium alone. This novel finding suggests that under low pH conditions lactobacilli are capable
of using biogenic amines as nutrient sources. The buffering capacity of vaginal fluids has been
previously suggested as an indicator of reproductive health (Noguchi et al., 2016). Thus,
approaches that aid in the maintenance of an acidic environment, such as the use of prebiotics
(Collins et al., 2017), are highly relevant to regulate the concentration of biogenic amines,
thereby preventing dysbiosis and malodour.
Previous observations determined that biogenic amine exposure slowed down and reduced the
growth capacity of lactobacilli (Borgogna et al., 2021). However, we identified that this
inhibitory effect can be reversed under ideal pH conditions. This might explain why some
lactobacilli strains can produce biogenic amines whereby some produce small amounts of
biogenic amines to support the growth of others, thereby maintaining an acidic environment that
prevents the proliferation of pathogenic bacteria.
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The microbiota study on vaginal samples showed that at concentrations of biogenic amines
similar to those found in the vaginal fluids of patients with BV, Lactobacillus are depleted,
potentially due to an increase in pH. This, in turn, allows for further proliferation of pathogens
towards a state of dysbiosis. Furthermore, only media containing cadaverine had the ability to
significantly decrease the proportion of Lactobacillus spp., suggesting that this compound plays
a key role in the infection process and onset of malodour. The impact of other amines is not clear
and should be further explored with larger sample sizes.
Overall, these findings provide a strong rationale for assessing candidate probiotic lactobacilli
strains for their capacity to degrade biogenic amines. This study also highlights the relevance of
maintaining a low pH in the vaginal environment, since this can turn biogenic amines from
inhibitory compounds to energy sources that support the growth of lactobacilli.
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Chapter 5

5

Topical probiotics for women’s urogenital health: selection of the
best oil-based vehicle

This chapter is reproduced from: Puebla-Barragan, S., Lamb, B., Jafelice, S., Reid, G. Topical
probiotics for women’s urogenital health: selection of the best oil-based vehicle. [Manuscript
submitted for publication]

5.1

Abstract

Vaginal care products are widely used by women to relief discomfort such as pain, itching, or
malodour, all of which are commonly caused by conditions resulting from microbiota
dysbiosis. Previous studies showed that probiotic strains Lacticaseibacillus (formerly
Lactobacillus) rhamnosus GR-1 (LGR-1) and Limosilactobacillus (formerly Lactobacillus)
reuteri RC-14 (LRC-14), can aid in restoring homeostasis in the vaginal microbiome when
taken orally. A topical product containing these strains could be of value for reducing
malodour and improving quality of life. However, the formulation of such a product is a
challenge, given that its ingredients must maintain shelf-life viability by excluding moisture.
Here, we tested petroleum jelly, mineral oil, coconut oil, and olive oil for how well they
maintained the viability of freeze-dried probiotic strains over a six-month timeframe. None of
the oils caused excessive loss of bacterial viability, with petroleum jelly and coconut oil
showing the most promise. Based on existing knowledge of these oils on the female genitalia,
coconut oil and petroleum jelly could be suitable probiotic carriers for clinical testing.

5.2

Introduction

Globally, feminine hygiene product revenue amounts to over 38 billion dollars, with a growth of
3.24% expected annually (Feminine Hygiene-Worldwide, n.d.).These products include washes,
wipes, creams and sprays intended to clean, soothe, and treat the vaginal area. They are marketed
for daily use or to relieve symptoms such as malodour. Although these products are intended to
maintain vaginal comfort, many of them may induce adverse effects and disrupt the vaginal
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microbiota (Chen et al., 2017; Fashemi et al., 2013; Jenkins et al., 2021), inducing a state of
dysbiosis that can predispose women to conditions such as bacterial vaginosis (BV), urinary tract
infection (UTI), pregnancy complications (Hillier et al., 1995), and sexually transmitted diseases
(Martin et al., 1999), as well as have a negative emotional impact on wellbeing (Bilardi et al.,
2013). Therefore, new topical over-the-counter (OTC) therapies could be beneficial if they
relieve the cause of aberrant symptoms and signs, and if they help maintain and restore vaginal
homeostasis.
Probiotics, defined as “live microorganisms that, when administered in adequate amounts, confer
a health benefit on the host” (Hill et al., 2014), have shown potential to improve female
urogenital health. Lactobacillus species are dominant in the vaginal microbiome and have
properties that contribute to health, such as lactic acid production (Tachedjian et al., 2017) and
various mechanisms that compete with pathogens (D’Alessandro et al., 2021). Lacticaseibacillus
(formerly Lactobacillus) rhamnosus GR-1 (LGR-1), taken orally, aids to maintain vaginal health
and is the most studied probiotic strain for vaginal health (Petrova et al., 2021). Genomic
analysis revealed that it is well adapted to the vaginal environment, specifically, due to a unique
exopolysaccharide production cluster and its ability to metabolize lactose and maltose, as well as
having increased resistance to oxidative stress (Macklaim et al., 2015).
Another strain of interest, Limosilactobacillus (formerly Lactobacillus) reuteri RC-14 (LRC-14),
in combination with LGR-1 can reduce infection recurrence (Reid, 2017; Vujic et al., 2013). This
combination of strains also has antifungal activity against common uropathogenic yeast Candida
albicans (Martinez et al., 2009a), and reduces the symptoms of vulvovaginal candidiasis (i.e.
discharge, itching, and dysuria), when used in conjunction with an antifungal agent (Martinez et
al., 2009b). Furthermore, the symbiotic relationship between strains LGR-1 and LRC-14 can aid
in the recovery from dysbiosis, replenishing indigenous species such as Lactobacillus crispatus
and Lactobacillus iners, which are present in high abundance in healthy vagina (Macklaim et al.,
2015).
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The aim of the present study was to test the viability of a commercial blend of LGR-1 and LRC14 over a period of 6 months in olive oil, mineral oil, coconut oil, and petroleum jelly, as a
means of developing a topical application of strains to counter pathogens and malodour. Current
cream and oil-based products are invariably not probiotic by definition, nor do they guarantee
that their ingredients can retain the viability of the bacterial contents (Puebla-Barragan & Reid,
2021). The use of preservatives with bactericidal activity is ill advised unless the compounds
have proven safety in humans. However, this creates the problem of an increased risk of
contaminants being in products. The use of oil-based compounds has the advantage of reduced
(or null) water content makings them less prone to contamination (Puebla-Barragan & Reid,
2021).
The oils used in the present study can be categorized as plant or petrolatum-based. The former
includes olive oil and coconut oil, commonly used in cosmetics due to their low cost and
moisturizing properties. Both oils are composed of 95% triglycerides and have been shown to act
as an emollient and improve skin barrier function (Sarkar et al., 2017; Vaughn et al., 2018).
Petroleum jelly and mineral oil are petrolatum-based and have a long standing history of use in
dermatology, dating back to the 1800s (Draelos, 2018). These oils are not absorbed into the skin,
have a reduced allergenic profile, can act as an occlusives that reduce moisture loss (Chuberre et
al., 2019; Patzelt et al., 2012) and are highly stable (Nash et al., 1996; Rawlings & Lombard,
2012).

5.3
5.3.1

Materials and methods
Oils

Petroleum jelly (Vaseline, Walmart), mineral oil (Life, Shopper’s Drug Mart), unrefined coconut
oil (Nutiva, Walmart), and extra virgin olive oil (Gallo, Walmart), were purchased from local
stores and kept under sterile conditions throughout the duration of the experiment.

5.3.2

Microorganisms

Capsules from a commercial probiotic, stating to contain 5 billion CFUs (colony forming units)
of a blend of freeze-dried LRC-14 and LGR-1, were used in this study. Contents consisted of 1 g
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of bacteria-containing powder along with the following excipients: glucose anhydrate,
microcrystalline cellulose, potato starch, magnesium stereate, gelatin, titanium dioxide, and milk.

5.3.3

Immersion of bacteria in the oil vehicles

Capsules were opened and their entire contents were added to 2 mL tubes with 500 µL of each
oil, and vortexed for 3 minutes. Control consisted of powder only. Petroleum jelly and coconut
oil were liquified by incubation in a heating block (40°C) for 3 minutes prior to vortexing. Five
replicates were used per oil per time point. Samples in petroleum jelly and coconut oil solidified
after the final vortexing step and remained in this state until extraction.
Tubes were stored for 6 months in a dry ice cube in the dark at a temperature of 20°C ± 2 and at
a relative humidity of 50% ± 5 (temperature and humidity were monitored using a ThermoPro
TP50 digital hygrometer). Five tubes were prepared for each time-point for each treatment and
discarded after each measurement.

5.3.4

Bacterial extraction

The contents of the oils were extracted by adding 500 µL of sterile phosphate buffered saline
(PBS, pH 7.4), vortexing for 5 minutes, and centrifuged at 5000 x g for 15 minutes. PBS was
heated to 40°C before being added to the samples with petroleum jelly.
After centrifugation, two layers were formed, PBS with the precipitated bacteria at the bottom,
and the oil at the top. Coconut, olive, and mineral oils were removed with a Pasteur pipette, and
petroleum jelly with a sterile scoopula. Then, tubes were vortexed for 1 minute to thoroughly
resuspend the contents.

5.3.5

Bacterial quantification

Measurements were made at 0, 1, 2, 3, 4, 5, and 6 months. Serial dilutions and CFU enumeration
were performed using the drop plate method, which involved inoculating 12 mL of Man-RogosaSharpe (MRS) (De Man et al., 1960) agar plates with rows of 5 μL drops of PBS containing
bacteria using a multichannel pipette. Each row was a miniature serial dilution with each drop
down the row having a dilution factor increased 10-fold. The agar plate was incubated
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anaerobically for 24 h at 37°C, and the number of colonies was determined by counting the row
corresponding to the 108 dilution.

5.3.6

Statistical analysis

The proportion of viable bacteria remaining in comparison to time 0 was calculated for each
treatment at each time point. Statistical analysis was carried out in RStudio V1.2.1335, using the
‘emmeans’ package V1.6.0 (Lenth, 2021) factorial two-way analysis of variance (ANOVA) with
the Dunnett method post-hoc for multiple comparisons was used to calculate statistical
significance. Data was plotted using ‘ggplot2’ (Wickham, 2016).

5.4
5.4.1

Results
Survival of freeze-dried probiotics stored in different oil vehicles

The percentage of bacterial survival is shown in Figure 5.1. Regardless of the treatment, all
samples decreased in viability across time points, including the control, which consisted on
powder only. After 6 months, all samples had an average reduction in viability of 59.3%. After 3
months, samples stored in coconut oil showed a significantly less viable than those in the control.
Petroleum jelly retained the viability of the probiotics significantly better than the control after 5
months of storage.
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Figure 5.1 Effect of different oils on the viability of freeze-dried probiotics
Proportion of CFUs remaining at time 0 and after months 1-6. One gram of a commercial blend
of LGR-1 and LRC-14 was immersed in 500 µL of petroleum jelly (blue line, squared symbols),
mineral oil (orange line, circular symbols), coconut oil (pink line, triangular symbols), or olive
oil (green line, diamond symbols). The control consisted on freeze-dried bacteria and excipients
only. Five independent experiments were carried out at every time point per treatment. The
100% represents 2 billion live organisms. Statistical significance was calculated with a factorial
two-way analysis of variance (ANOVA) with the Dunnett method post-hoc for multiple
comparisons (** p ≤ 0.001).
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5.5

Discussion

The present study showed that several mineral oils approved for vaginal use can be used to retain
urogenital probiotic strain viability over six months. The use of personal care products either
externally or intravaginally is common practice around the world (Brown et al., 2013; Crann et
al., 2018; Hassan et al., 2007). These include vaginal washes, lubricants, and wipes ostensibly to
relieve itching, dryness, malodour, or burning sensations, as well as to improve their sexual lives.
Of critical importance in using local applications, in addition to safety, is that strains are selected
for appropriate properties and they can survive in the delivery vehicle. Unfortunately, some
locally applied products can increase the risk of vaginal dysbiosis and subsequent BV or UTI
(Brown et al., 2013, 2016; Chen et al., 2017).
There is generally a loss of bacterial viability within freeze dried preparations. The product label
states a guarantee that at least 1 billion of CFU would remain viable at the end of the shelf life of
the product (approximately three years after manufacture), which would represent 20% of the
initial amount added. The viability of two probiotic strains was not reduced in mineral and olive
oil compared to controls, indicating the oils were not antimicrobial. Of note, the powder used for
these studies was from capsules which also provide protection from viability loss (Wilcox et al.,
2020).
Both coconut oil and petroleum jelly are solid at room temperature, but they behaved differently.
The strains incubated in coconut oil had decreased viability by almost 20% more after three
months, yet no further loss occurred. The explanation is not known but suggests an equilibrium
is reached perhaps after adaptation to the oil’s properties. The viable count for strains incubated
in petroleum oil was higher at five compared to four months which we suspect was within
experimental error despite the statistical significance, since the monthly trend followed a similar
pattern between months one to four then five to six.
The nature of the coconut oil and petroleum jelly provided a relatively even dispersion of the
bacterial powder. This is a desired attribute in this type of product, to ensure that every
application contains the probiotic organisms. Therefore, if approximately 5 mL was dispensed
from a tube, at six months, it would still be expected to deliver one billion live organisms.
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The knowledge of the impact of these oils in the vaginal microbiome is sparse. This is a factor
that must be considered before formulating a product of this nature. External use of mineral oil is
common (i.e. perianally or on the vulval area) (Araújo & Oliveira, 2008; Thorstensen &
Birenbaum, 2012), and despite it being linked to adverse reactions (Crann et al., 2018) and
Candida colonization (Brown et al., 2013), it is a mainstay ingredient of medical pomades
intended for vaginal use (Tirri, 2011).
In considering the use of petroleum jelly to deliver probiotic bacteria, it should be noted that
when applied intravaginally it is associated with a lower prevalence of Lactobacillus species and
an increase in the abundance of BV-associated morphotypes (Brown et al., 2013; Hassan et al.,
2007). Yet, similarly to mineral oil, external use of petroleum jelly is generally considered safe
and is common in clinical practice, either perianally (Araújo & Oliveira, 2008), or on the skin of
vulval vestibule to treat symptoms associated to dermatological inflammatory conditions of the
vulva (Thorstensen & Birenbaum, 2012). The inclusion of lactobacilli strains antagonistic to BV
organisms, could prove to counter these negative attributes of the jelly in the vagina. Better still,
if the probiotic strains in petroleum jelly were only applied to the outer urogenital skin, this
would reduce further the risk of BV organisms propagating.
Olive oil has antimicrobial, antioxidant, and anti-inflammatory activities, mostly due to their
high content of phenolic compounds. However, little is known on its impact on the microbiota
(Cicerale et al., 2012). Its high content of oleic acid could harm the skin barrier and be an irritant,
thereby damaging the native microbiota, which could in turn allow pathological organisms to
colonize and cause inflammation (Vaughn et al., 2018). However, olive oil has been successfully
used intravaginally in a clinical setting to relief breast cancer patients of dyspareunia (genital
pain caused by intercourse) and it can also inhibit Candida species (Alwan & Alwan, 2019).
Although coconut oil was the only tested oil to show a significant decrease in viability, it is also
the one with most potential for vaginal health and, as mentioned previously, its ability to remain
solid at room temperature allows for a better dispersion of freeze-dried bacteria. Coconut oil
contains monolaurin, which is an antimicrobial monoglyceride formed from lauric acid, which is
a short fatty acid that can disrupt the membranes of microbial organisms; it is particularly
efficient at inhibiting common skin pathogens such as Propionibacterium acnes and
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Staphylococcus aureus. However, this antimicrobial effect could be the reason why there was a
drastic decrease in the viability of probiotics after three months so, if a probiotic product were to
be formulated based on coconut oil, it would be important to market it as to be used no more than
2 months after purchase (Vaughn, 2018). This could pose challenges for distribution, perhaps
requiring refrigeration. Coconut oil has been shown to enrich commensals and decrease the
expression of the pathogenesis pathway of fungi found on the scalp (Saxena et al., 2021). In
addition, it is highly effective in reducing Candida albicans (Ogbolu et al., 2007) and inhibiting
the production of exotoxins by vaginal pathogens (Schlievert et al., 2008). When applied
vaginally to rhesus macaques, coconut oil did not affect the compositions of the vaginal
microbiota (Schlievert et al., 2008).
In summary, the present study suggests that petroleum jelly and coconut oil are good candidates
as vehicles for the delivery of topical probiotics to the external female genitalia. Future studies
could assess the impact on the vaginal microbiota and metabolic read-out as well as the effects
on epithelial cells. A previous study has shown that application of LGR-1 to the vagina can
stimulate antimicrobial peptides (Jayaram et al., 2014), making it a good choice for this type of
application. An advantage of applying live bacteria rather than compounds such as lactic acid
(Bruning et al., 2020) is that the probiotic strains can adapt to the environment and produce other
substances important to health maintenance.
It is also clear that packaging will play a major role for this type of product, both for enhancing
viability, as well as to guarantee it is designed to be used within the ideal shelf-life time.
Additionally, a product that has to be kept in refrigeration would be an excellent approach to
extend the utility life of the product while avoiding the use of additional ingredients (e.g.
preservatives) that could affect the bacteria in the product as well as the urogenital microbiota of
the consumer. Preparations formulated by apothecaries could be made by adding freeze-dried
bacteria to the carrier with a defined short-term shelf life, this would warrant the viability of the
probiotics.
Of note, all of the tested oils retained the viability of probiotics in a comparable manner as the
control, suggesting that they can also be used when formulating topical probiotic products with
other stains that target different organs, such as the skin. Still, there is a major area of
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opportunity in the investigation of impact of these and other lipids on the microbiota of different
organs. It is pressing to bridge these gaps in knowledge to widen the uses and benefits of
probiotics.

5.6
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Chapter 6

6

General discussion

Interest in probiotic research and applications has increased dramatically throughout the past two
decades (Puebla-Barragan & Reid, 2019). However, challenges remain, particularly that although
new products claiming to be probiotic are flooding the market, the vast majority do not comply
with the requirements to be labelled as such (Puebla-Barragan & Reid, 2021).
A key aspect of probiotics is that they must provide a documented health benefit on the host
(FAO/WHO Working Group, 2002; Hill et al., 2014). Therefore, it is crucial to keep
investigating different strains with specific benefits in mind, rather than proposing them as a one
cure-all (Reid et al., 2019).
On that note, certain probiotic strains have been well documented to aid in the maintenance and
restoration of women’s urogenital health; the most prominent strains for this purpose are
Lacticaseibacillus rhamnosus GR-1 (LGR-1) and Limosilactobacillus reuteri RC-14 (LRC-14)
(Petrova et al., 2018; Reid et al., 2003). Other probiotics, such as Lactobacillus crispatus CTV05, are being tested for intravaginal use (Hemmerling et al., 2009; Stapleton et al., 2011)That
strains has shown to reduce recurrence of urinary tract infection (UTI), but is not being pursued
further.
The approach taken by our lab is to focus on strain properties and align them with the target for
their use. In doing so, it is important to identify ailments amenable to probiotic applications. This
thesis focused on urogenital malodour, a problem that affects millions of women around the
globe (Bilardi et al., 2013), but one that has been overlooked such that no effective solution
exists yet. The idea being explored was whether lactobacilli strains could counter the production
of malodourous compounds or degrade them.

6.1

The chemistry of malodour in the female urogenital tract

The female urogenital microbiome in healthy women is populated mostly by Lactobacillus
species (Miller et al, 2016; Ravel et al., 2011). When homeostasis is lost and a state of dysbiosis
arises, the host become susceptible to infection. Bacterial vaginosis (BV) and urinary tract
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infection (UTI) are two of the most prevalent conditions that can result from the disruption of the
vaginal microbiome (Salvatore et al., 2011; Tandogdu & Wagenlehner, 2016). A factor that these
conditions have in common is malodour, which is one of the main reasons patients seek medical
advice.
Previous work in our lab by Dr. Amy McMillan used metabolomics and genomics to better
characterize the vaginal microbiome. One of her main findings was that the biogenic amines
(BAs) cadaverine, putrescine, tyramine, and trimethylamine (TMA), were biomarkers of BV
(McMillan et al., 2015). This suggests that, by targeting these compounds, relief from urogenital
malodour could be provided.
At the beginning of my doctoral studies, there was a tremendous knowledge gap in terms of
which compounds were responsible for malodour during the course of a UTI. Moreover, this sign
has been commonly overlooked both in research and clinical settings (Sj et al., 2004;
Subramanian et al., 2012). The study outlined in Chapter 1 established metabolomic
methodologies and determined that BAs were responsible for urinary malodour (PueblaBarragan et al., 2020)

6.2

Lactobacilli and biogenic amines: a complex relationship

Preliminary experiments suggested that BAs affected the growth and metabolism of indigenous
lactobacilli, thereby reducing the defenses of the urogenital tract and promoting dysbiosis
(Borgogna et al., 2021; Nelson et al., 2015). Findings from Chapters 3 and 4 confirmed that there
is indeed an interaction between vaginal lactobacilli and BAs since. Some lactobacilli were
found able to degrade these compounds while others used them as an energy source. Genomic
analyses showed that biocatalytic and biosynthetic pathways were present.
In Chapter 4, these interactions were further investigated, and it was discovered that although
BAs indeed reduce the growth of the mainstay vaginal species Lactobacillus crispatus, when pH
conditions remain low these organisms can use the amines as energy sources that allow for better
and faster growth. This implies a change in paradigms were, compounds previously thought to
negatively impact vaginal lactobacilli (Borgogna et al., 2021), can actually have the opposite
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effect and be beneficial under the right conditions. Future studies should further investigate this
relationship in order to develop a strategy to manage the levels of malodour.
Chapter 4 also proved that L. crispatus undergoes metabolic adaptations when exposed to BAs,
making them less susceptible to these compounds at higher vaginal pH conditions.
Overall, this thesis revealed the potential to develop probiotics capable of degrading BAs,
maintaining a pH less than 4.7, and allowing the indigenous strains to use BAs to retain
homeostasis. Specific prebiotics (Collins et al., 2017) and buffering products (Mayer et al., 2001)
could further assist in lactobacilli stimulation. Although probiotic strains LGR-1 and LRC-14 did
not significantly degrade BAs, they can robustly maintain an acidic environment through the
production of lactic acid (Reid et al., 2003). Nonetheless, further studies, with human subjects
and larger sample sizes are still required to better characterize the mechanisms and relationships
between biogenic amines and vaginal lactobacilli.

6.3

Topical probiotics: an efficient solution

The significant burden that urogenital malodour represents for women, as well as the lack of
effective and safe treatments, has led to the widespread use of feminine products such as lotions,
wipes and vaginal douches, which, are not only ineffective since at best they only mask the
odours, but they actually increase the risk of vaginal dysbiosis, making users more prone to
infection (Fashemi et al., 2013). The fact that these products exist and are commonly purchased,
reflects the market demand for treatments.
The use of probiotics has already shown promise to restore and maintain homeostasis which,
albeit indirectly, aids to reduce malodour by preventing the establishment of pathogens that
produce them in large quantities. In cases where infection arises, antibiotics do not provide full
relief from signs and symptoms for several days, and therefore there is a place for product that
can provide faster relief by degrading malodourous compounds. Our findings from Chapter 3 and
4 confirmed that there are several strains, particularly of L. crispatus, capable to significantly
decrease the amount of BAs. The discovery that cell-free extracts can achieve the same result
opens up the possibility for formulations accessible to over-the-counter purchase. In order to
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develop a topical application that contains live lactobacilli as well as the cell-free extracts, the
delivery system must support the retention of the viable organisms.
If a topical probiotic product were to be developed, there are three key factors to take into
account: 1) Bacteria should remain live throughout the shelf-life, 2) The formula must have a
low or null water content to prevent contamination, and 3) All components should be safe for
human use (Hill et al., 2014; Puebla-Barragan & Reid, 2021; Tkachenko et al., 2017). The results
of the proof-of-concept experiments carried out in chapter 5 suggest that an excellent approach
would be an oil-based formula, predominantly based on coconut oil or petroleum jelly or as a
mixture of different oils. Coconut oil appears to be the most promising choice since there is
evidence that it can be favourable for the vaginal microbiota, although based on our observations
such product would have a short shelf-life and require specific packaging and storage conditions
(Anzaku, 2017; Ogbolu et al., 2007). However, despite products being designed for intravaginal
application, there is a major knowledge gap on the impact of their ingredients on the vaginal
microbiota (Brown et al., 2013; Fashemi et al., 2013; Łaniewski et al., 2021). More research on
this is needed, which takes into account the biochemistry of the different ingredients in personal
care formulas, as well as their interaction with probiotic strains. Although our findings in this
matter are preliminary, they are the first step towards better understanding of the impact of
vehicles in probiotics. Next steps should focus on metabolic and transcriptomic adaptations that
bacteria might undergo due to exposure to different ingredients, with a view of getting a clearer
picture of how they can impact the health benefits that the product aims to have on the host.

6.4

Where is the field heading?

The market for probiotic products is growing at a very steady rate. Unfortunately current
regulations are not sufficient to guarantee that what consumers acquire is indeed a probiotic
(FactMR, 2020; Foligné et al., 2013). The term ‘probiotic’ has become a buzz word too often
misused to inflate the merits of some products (Puebla-Barragan & Reid, 2019; 2021). While the
onus is on regulatory agencies to prevent misleading claims, the scientific community should
provide stewardship by demanding that strains only be termed probiotic if backed by appropriate
evidence.
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In terms of urogenital health, it should be possible to create rapid tests that identify microbiota
and metabolic profiles thereby improving the accuracy in diagnoses. In theory this should allow
physicians to tailor a better management plan (Cartwright et al., 2018; Hong et al., 2016), but
with no alternatives to antibiotics, this is difficult. Hopefully, if probiotic strains and compounds
that degrade BAs can be developed as efficacious products, they could either be prescribed or
purchased by women to restore and maintain urogenital health. This will be an interesting
challenge for treating urinary malodour since these compounds are likely produced by
constituents of the bladder and urethral microbiota. Two approaches are conceivable: ingestion
of prebiotic compounds to stimulate the lactobacilli within the microbiota; and topical
application of the BA-degrading lactobacilli to see if they ascend the urethra and influence the
bladder microbiome. Hopefully the work described in this thesis will help towards these goals
and lead to tangible improvements in the health of women.

6.5

References

Anzaku, A. A. (2017). Antimicrobial activity of coconut oil and its derivative (lauric acid) on
some selected clinical isolates. International Journal of Medical Science and Clinical
Inventions, 4, 3173-3177.
Bilardi, J. E., Walker, S., Temple-Smith, M., McNair, R., Mooney-Somers, J., Bellhouse, C.,
Fairley, C. K., Chen, M. Y., & Bradshaw, C. (2013). The burden of bacterial vaginosis:
women’s experience of the physical, emotional, sexual and social impact of living with
recurrent bacterial vaginosis. PLoS One, 8, e74378.
Borgogna, J., Shardell, M. D., Grace, S. G., Santori, E. K., Americus, B., Li, Z., Ulanov, A.,
Forney, L., Nelson, T. M., Brotman, R. M., Ravel, J., & Yeoman, C. J. (2021). Biogenic
amines increase the odds of bacterial vaginosis and affect the growth of and lactic acid
production by vaginal Lactobacillus spp. Applied and Environmental Microbiology, 87, 1–
16.
Brown, J., Hess, K., Brown, S., Murphy, C., Waldman, A., & Hezareh, M. (2013). Intravaginal
practices and risk of bacterial vaginosis and candidiasis infection among a cohort of women
in the United States. Obstetrics and Gynecology, 121(4), 773–780.

144
Cartwright, C. P., Pherson, A. J., Harris, A. B., Clancey, M. S., & Nye, M. B. (2018).
Multicenter study establishing the clinical validity of a nucleic-acid amplification–based
assay for the diagnosis of bacterial vaginosis. Diagnostic Microbiology and Infectious
Disease, 92, 173–178.
Collins, S. L., McMillan, A., Seney, S., van der Veer, C., Kort, R., Sumarah, M. W., & Reid, G.
(2017). Promising prebiotic candidate established by evaluation of lactitol, lactulose,
raffinose, and oligofructose for maintenance of a Lactobacillus -dominated vaginal
microbiota. Applied and Environmental Microbiology, 84, e02200-17.
FactMR. (2020). Probiotic cosmetic products market forecast, trend analysis and competition
tracking - global market insights 2020 to 2030. Available at:
https://www.factmr.com/report/4188/probiotic-cosmetic-products-market
FAO/WHO Working Group. (2002). Report of a joint FAO/WHO expert consultation on
evaluation of health and nutrition properties of probiotics in food including powder milk
with live lactic acid bacteria. Available at: http://www.fao.org/3/a0512e/a0512e.pdf
Fashemi, B., Delaney, M. L., Onderdonk, A. B., & Fichorova, R. N. (2013). Effects of feminine
hygiene products on the vaginal mucosal biome. Microbial Ecology in Health & Disease,
24, 19703.
Foligné, B., Daniel, C., & Pot, B. (2013). Probiotics from research to market: the possibilities,
risks and challenges. Current Opinion in Microbiology, 16, 284–292.
Hemmerling, A., Harrison, W., Schroeder, A., Park, J., Korn, A., Shiboski, S., & Cohen, C. R.
(2009). Phase 1 dose-ranging safety trial of Lactobacillus crispatus CTV-05 for the
prevention of bacterial vaginosis. Sexually Transmitted Diseases, 36, 564–569.
Hill, C., Guarner, F., Reid, G., Gibson, G. R., Merenstein, D. J., Pot, B., Morelli, L., Canani, R.
B., Flint, H. J., Salminen, S., Calder, P. C., & Sanders, M. E. (2014). The International
Scientific Association for Probiotics and Prebiotics consensus statement on the scope and
appropriate use of the term probiotic. Nature Reviews Gastroenterology & Hepatology, 11,
506–514.

145
Hong, K. H., Hong, S. K., Cho, S. I., Ra, E., Han, K. H., Kang, S. B., Kim, E.-C., Park, S. S., &
Seong, M.-W. (2016). Analysis of the vaginal microbiome by next-generation sequencing
and evaluation of its performance as a clinical diagnostic tool in vaginitis. Annals of
Laboratory Medicine, 36, 441–449.
Łaniewski, P., Owen, K. A., Khnanisho, M., Brotman, R. M., & Herbst-Kralovetz, M. M. (2021).
Clinical and personal lubricants impact the growth of vaginal Lactobacillus species and
colonization of vaginal epithelial cells: an in vitro study. Sexually Transmitted Diseases, 48,
63–70.
Mayer, K. H., Peipert, J., Fleming, T., Fullem, A., Moench, T., Cu-Uvin, S., Bentley, M.,
Chesney, M., & Rosenberg, Z. (2001). Safety and tolerability of BufferGel, a novel vaginal
microbicide, in women in the United States. Clinical Infectious Diseases, 32, 476–482.
McMillan, A., Rulisa, S., Sumarah, M., Macklaim, J. M., Renaud, J., Bisanz, J. E., Gloor, G. B.,
& Reid, G. (2015). A multi-platform metabolomics approach identifies highly specific
biomarkers of bacterial diversity in the vagina of pregnant and non-pregnant women.
Scientific Reports, 5(May), 1–14.
Nelson, T. M., Borgogna, J., Brotman, R. M., Ravel, J., Walk, S. T., & Yeoman, C. J. (2015).
Vaginal biogenic amines: biomarkers of bacterial vaginosis or precursors to vaginal
dysbiosis? Frontiers in Physiology, 6, 1–15.
Miller, E. A., Beasley, D. E., Dunn, R. R., & Archie, E. A. (2016). Lactobacilli dominance and
vaginal pH: why is the human vaginal microbiome unique? Frontiers in Microbiology, 7,
1936.
Ogbolu, D. O., Oni, A. A., Daini, O. A., & Oloko, A. P. (2007). In vitro antimicrobial properties
of coconut oil on Candida species in Ibadan, Nigeria. Journal of Medicinal Food, 10, 384–
387.
Petrova, M. I., Macklaim, J. M., Wuyts, S., Verhoeven, T., Vanderleyden, J., Gloor, G. B.,
Lebeer, S., & Reid, G. (2018). Comparative genomic and phenotypic analysis of the vaginal
probiotic Lactobacillus rhamnosus GR-1. Frontiers in Microbiology, 9, 1278.

146
Puebla-Barragan, S., & Reid, G. (2019). Forty-five-year evolution of probiotic therapy.
Microbial Cell, 6, 184–196.
Puebla-Barragan, S., & Reid, G. (2021). Probiotics in cosmetic and personal care products:
trends and challenges. Molecules, 26, 1249.
Puebla-Barragan, S., Renaud, J., Sumarah, M., & Reid, G. (2020). Malodorous biogenic amines
in Escherichia coli-caused urinary tract infections in women—a metabolomics approach.
Scientific Reports, 10, 9703.
Ravel, J., Gajer, P., Abdo, Z., Schneider, G. M., Koenig, S. S. K., McCulle, S. L., Karlebach, S.,
Gorle, R., Russell, J., Tacket, C. O., Brotman, R. M., Davis, C. C., Ault, K., Peralta, L., &
Forney, L. J. (2011). Vaginal microbiome of reproductive-age women. Proceedings of the
National Academy of Sciences of the United States of America, 108, 4680–4687.
Reid, G., Charbonneau, D., Erb, J., Kochanowski, B., Beuerman, D., Poehner, R., & Bruce, A.
W. (2003). Oral use of Lactobacillus rhamnosus GR-1 and L. fermentum RC-14
significantly alters vaginal flora: randomized, placebo-controlled trial in 64 healthy women.
FEMS Immunology and Medical Microbiology, 35, 131–134.
Reid, G., Gadir, A. A., & Dhir, R. (2019). Probiotics: reiterating what they are and what they are
not. Frontiers in Microbiology, 10, 424.
Salvatore, S., Salvatore, S., Cattoni, E., Siesto, G., Serati, M., Sorice, P., & Torella, M. (2011).
Urinary tract infections in women. European Journal of Obstetrics Gynecology and
Reproductive Biology, 156, 131–136.
Sj, M., Paur R, & Lindseth G. (2004). Urinary tract infections. Does the smell really tell? J
Gerontol Nurs, 30, 4–9.
Stapleton, A. E., Au-Yeung, M., Hooton, T. M., Fredricks, D. N., Roberts, P. L., Czaja, C. A.,
Yarova-Yarovaya, Y., Fiedler, T., Cox, M., & Stamm, W. E. (2011). Randomized, placebocontrolled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for
prevention of recurrent urinary tract infection. Clinical Infectious Diseases, 52, 1212–1217.

147
Subramanian, C., Nyirjesy, P., & Sobel, J. D. (2012). Genital malodor in women: a modern
reappraisal. Journal of Lower Genital Tract Disease, 16, 49–55.
Tandogdu, Z., & Wagenlehner, F. M. E. (2016). Global epidemiology of urinary tract infections.
Current Opinion in Infectious Diseases, 29, 73–79.
Tkachenko, N., Chagarovskyi, O., Dets, N., Sevastyanova, E., & Lanzhenko, L. (2017). “Living”
and “probiotic” cosmetics: modern view and definitions. Food Science and Technology, 11, 735.

148

Appendix A: content license for Microbial cell

149

Appendix B: content license for Molecules

150

Appendix C: content license for Scientific Reports

151

Appendix D: supplementary material for Chapter 4

Figure S1. PCoA of predicted functional capacity of strains based on mapping of genes to the
EggNOG database. Each letter represents a different functional category. [A] RNA processing
and modification, [B] Chromatin structure and dynamics, [C] Energy production and conversion,
[D] Cell cycle control, cell division, chromosome partitioning, [E] Amino acid transport and
metabolism, [F] Nucleotide transport and metabolism, [G] Carbohydrate transport and
metabolism, [H] Coenzyme transport and metabolism, [I] Lipid transport and metabolism, [J]
Translation, ribosomal structure and biogenesis, [K] Transcription, [L] Replication,
recombination and repair, [M] Cell wall/membrane/envelope biogenesis, [N] Cell motility, [O]
Post-translational modification, protein turnover, and chaperones, [P] Inorganic ion transport and
metabolism, [Q] Secondary metabolites biosynthesis, transport, and catabolism, [R] General
function prediction only, [S] Function unknown, [T] Signal transduction mechanisms, [U]
Intracellular trafficking, secretion, and vesicular transport, [V] Defense mechanisms, and [W]
Extracellular structures. Groups with <5 genes per strain were removed.
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Figure S2. Zone of inhibition measurements (mm) from agar well diffusion assays
featuring L. crispatus supernatants that were heated, treated with trypsin, and unheated
against E. faecium indicator strain.
Strains were grown for 24 hours on CBA plates and the individual supernatants were
collected using the freeze/thaw method. L. crispatus supernatant volumes were then
normalized, neutralized using HCl and NaOH, and filter sterilized. Additional CBA plates
as controls without bacterial growth, were subjected to the same incubation and collection
method. 1/3 each supernatant was heated to 85°C for 45 minutes, and 1/3 of the
supernatants were treated with 1mg/mL of trypsin. Included in the controls was a sample
that was neutralized, one that was left at its original pH, one that was brought to a pH of 5
using lactic acid and then neutralized using NaOH, and one that was brought to a pH of 5.
All controls were then filter sterilized. 250µl of the indicator strain was plated on m17
agar, 1cm holes were bored, and 50 µl of each supernatant was deposited into each well.
Following incubation at 37°C for 48 hours the zones of inhibition were measured (N=4).
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Table S1. L. crispatus strains used in this study. Strains were isolated from human vaginal swabs
with Lactobacillus-dominated vaginal microbiota (LVM) or dysbiotic vaginal microbiota
(DVM). BioSample Database accession numbers (NCBI: PRJNA390079) and bacterial
collection strain numbers.
Strain

BioSample
Database
DDBJ/ENA/Gen
Bank

RL02

SAMN07213039

NCCB 100711

RL21

SAMN07213201

NCCB 100723

RL03

SAMN07213108

not available

RL22

not available

not available

RL05

SAMN07213187

not available

RL23

SAMN07213203

NCCB 100724

RL06

SAMN07213188

not available

RL24

SAMN07213204

NCCB 100725

RL07

SAMN07213189

NCCB 100713

RL25

SAMN07213205

NCCB 100726

RL08

SAMN07213190

not available

RL26

SAMN07213206

not available

RL09

SAMN07213191

NCCB 100714

RL27

SAMN07213207

NCCB 100727

RL10

SAMN07213192

NCCB 100715

RL28

SAMN07213208

NCCB 100728

RL11

SAMN07213193

not available

RL29

SAMN07213209

not available

RL13

SAMN07213194

NCCB 100716

RL30

SAMN07213210

NCBB 100730

RL14

SAMN07213195

NCCB 100717

RL31

SAMN07213211

not available

RL15

SAMN07213196

NCCB 100718

RL32

SAMN07213212

not available

RL16

SAMN07213197

NCCB 100719

RL33

SAMN07213213

NCCB 100731

RL17

SAMN07213198

NCCB 100720

RL19

SAMN07213199

NCCB 100721

RL01

not available

not available

RL04

Not available

Not available

RL12

not available

not available

RL22

not available

not available

RL20

SAMN07213200

Collection

NCCB 100722

Strain

BioSample
Collection
Database
DDBJ/ENA/GenB
ank
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